Recent Additions

This page includes the documents that were newly added to the repository within the last 30 days.

All these words:

This exact word or phrase:

Any of these words:

None of these words:

Language:

Visit our Help Page for additional assistance

Select a Range:

Select a Format:

Custom Search Builder:

Custom Search Box

Visit our Help Page for additional assistance

Showing 1141 - 1160 of 2104 results

A 2024 Global Report on National Policy, Programmes, and Progress Towards Hepatitis B Elimination: Findings From 33 Hepatitis Elimination Profiles.

Hiebert-Suwondo, Lindsey ;

Manning, Jana

July 2025 | The Lancet. Gastroenterology & Hepatology, 2025, v. 10, no. 7

The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development the elimination of viral hepatitis. Profiles from 33 countries and territories show progress, towards elimination of hepatitis B with 24 (73%) of them meeting the 2025 WHO interim target of 0· ...

10/09/2026

Supporting Files

Title : A 2024 Global Report on National Policy, Programmes, and Progress Towards Hepatitis B Elimination: Findings From 33 Hepatitis Elimination Profiles. Personal Author(s) : Hiebert-Suwondo, Lindsey;Manning, Jana;Tohme, Rania A;Buti, Maria;Kondili, Loreta A;Spearman, C Wendy;Prabdial-Sing, Nishi;Turnier, Victoria;Lazarus, Jeffrey V;Waked, Imam;Ward, John W; Corporate Authors(s) : the National Hepatitis Elimination Profile Collaborators Published Date : July 2025 Pages in Document : 671-684 (28 pdf pages) Source : The Lancet. Gastroenterology & Hepatology, 2025, v. 10, no. 7 DOI : https://doi.org/10.1016/S2468-1253(25)00069-X Journal Title : The Lancet. Gastroenterology & Hepatology
Hiebert-Suwondo, L., Manning, J., Tohme, R. A., Buti, M., Kondili, L. A., Spearman, C. W., Prabdial-Sing, N., Turnier, V., Lazarus, J. V., Waked, I., & Ward, J. W. (2025). A 2024 Global Report on National Policy, Programmes, and Progress Towards Hepatitis B Elimination: Findings From 33 Hepatitis Elimination Profiles. The Lancet. Gastroenterology & Hepatology, 10(7). https://doi.org/10.1016/S2468-1253(25)00069-X

Hiebert-Suwondo, Lindsey, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, and Nishi Prabdial-Sing, et al.. "A 2024 Global Report on National Policy, Programmes, and Progress Towards Hepatitis B Elimination: Findings From 33 Hepatitis Elimination Profiles." The Lancet. Gastroenterology & Hepatology 10, no. 7 (2025). https://doi.org/10.1016/S2468-1253(25)00069-X.

Hiebert-Suwondo, Lindsey, et al. "A 2024 Global Report on National Policy, Programmes, and Progress Towards Hepatitis B Elimination: Findings From 33 Hepatitis Elimination Profiles." The Lancet. Gastroenterology & Hepatology, vol. 10, no. 7, 2025. Stacks. https://doi.org/10.1016/S2468-1253(25)00069-X.
Export RIS Citation Information. TY - Journal Article AU - Hiebert-Suwondo, Lindsey AU - Manning, Jana AU - Tohme, Rania A AU - Buti, Maria AU - Kondili, Loreta A AU - Spearman, C Wendy AU - Prabdial-Sing, Nishi AU - Turnier, Victoria AU - Lazarus, Jeffrey V AU - Waked, Imam AU - Ward, John W A2 - the National Hepatitis Elimination Profile Collaborators AB - The Coaltion for Global Hepatitis Elimination's National Hepatitis Elimination Profiles assess the status of national data, policy, and programme development the elimination of viral hepatitis. Profiles from 33 countries and territories show progress, towards elimination of hepatitis B with 24 (73%) of them meeting the 2025 WHO interim target of 0·5% or less HBsAg prevalence in children younger than 5 years. 22 (67%) of countries and territories profiled have policies for universal hepatitis B birth-dose vaccination of newborns. Access to hepatitis B testing and treatment, including removing HBsAg screening and hepatitis B treatment patient co-payments and simplifying treatment algorithms, remains suboptimal, especially in low-income and middle-income countries and territories. Of the seven profiled countries and territories meeting the 60% WHO 2025 diagnosis coverage target, all but one (Rwanda) is a high-income country or territory. No country or territory has met the WHO 2025 treatment target of at least 50% of people living with hepatitis B receiving treatment. The profiles guide national planning and identify priorities for resource mobilisation to further accelerate hepatitis B elimination. AB - Author manuscript AN - cdc:261391 C4 - PMC12308976 DO - https://doi.org/10.1016/S2468-1253(25)00069-X IS - 7 J2 - The Lancet. Gastroenterology & Hepatology KW - Antiviral Agents KW - Disease Eradication KW - Hepatitis B Surface Antigens KW - Global Health KW - Hepatitis B KW - Health Policy KW - Humans KW - Child, Preschool KW - Infant, Newborn KW - Hepatitis B Vaccines KW - World Health Organization KW - Humans KW - Hepatitis B KW - Disease Eradication KW - Global Health KW - Health Policy KW - Hepatitis B Vaccines KW - World Health Organization KW - Antiviral Agents KW - Hepatitis B Surface Antigens KW - Child, Preschool KW - Infant, Newborn LA - eng PY - 2025 T2 - The Lancet. Gastroenterology & Hepatology T2 - The Lancet. Gastroenterology & Hepatology, 2025, v. 10, no. 7 TI - A 2024 Global Report on National Policy, Programmes, and Progress Towards Hepatitis B Elimination: Findings From 33 Hepatitis Elimination Profiles. VL - 10 UR - https://stacks.cdc.gov/view/cdc/261391 ER -
Spirometric Pattern Transitions in a World Trade Center Occupational Cohort on Longitudinal Surveillance.

Weber, Jonathan ;

Zhang, Zitong

August 2025 | Respiratory Medicine, 2025, v. 244

Many workers and volunteers who participated in the rescue and recovery of the World Trade Center (WTC) disaster site in 2001-2002 manifest a heterogeneous group of chronic lower airway diseases, with variable spirometric patterns on longitudinal surveillance. We examined systematically the observed transitions among those spirometric patterns and ...

10/09/2026

Supporting Files

Title : Spirometric Pattern Transitions in a World Trade Center Occupational Cohort on Longitudinal Surveillance. Personal Author(s) : Weber, Jonathan;Zhang, Zitong;Doucette, John T.;Sood, Akshay;Celedón, Juan C.;de la Hoz, Rafael E.; Published Date : August 2025 Pages in Document : 108170 (17 pdf pages) Source : Respiratory Medicine, 2025, v. 244 DOI : https://doi.org/10.1016/j.rmed.2025.108170 Journal Title : Respiratory Medicine
Weber, J., Zhang, Z., Doucette, J. T., Sood, A., Celedón, J. C., & de la Hoz, R. E. (2025). Spirometric Pattern Transitions in a World Trade Center Occupational Cohort on Longitudinal Surveillance. Respiratory Medicine, 244. https://doi.org/10.1016/j.rmed.2025.108170

Weber, Jonathan, Zitong Zhang, John T. Doucette, Akshay Sood, Juan C. Celedón, and Rafael E. de la Hoz. "Spirometric Pattern Transitions in a World Trade Center Occupational Cohort on Longitudinal Surveillance." Respiratory Medicine 244 (2025). https://doi.org/10.1016/j.rmed.2025.108170.

Weber, Jonathan, et al. "Spirometric Pattern Transitions in a World Trade Center Occupational Cohort on Longitudinal Surveillance." Respiratory Medicine, vol. 244, 2025. Stacks. https://doi.org/10.1016/j.rmed.2025.108170.
Export RIS Citation Information. TY - Journal Article AU - Weber, Jonathan AU - Zhang, Zitong AU - Doucette, John T. AU - Sood, Akshay AU - Celedón, Juan C. AU - de la Hoz, Rafael E. AB - Many workers and volunteers who participated in the rescue and recovery of the World Trade Center (WTC) disaster site in 2001-2002 manifest a heterogeneous group of chronic lower airway diseases, with variable spirometric patterns on longitudinal surveillance. We examined systematically the observed transitions among those spirometric patterns and assessed their association with BMI and occupational WTC exposure intensity. AB - We selected 10,810 Mount Sinai WTC General Responders' Cohort members with at least three acceptable quality periodic spirometries (n = 56,312) performed between July 2002 and November 2019. We defined three spirometric patterns: (1) normal: prebronchodilator first-second forced expiratory volume (FEV AB - ), forced vital capacity (FVC), and FEV AB - /FVC ratio > lower limit of normal (LLN); (2) obstruction: pre-bronchodilator FEV AB - /FVC ratio<LLN; (3) low FVC: FVC < LLN and FEV AB - /FVC > LLN. We built a multi-state Markov-like model to analyze probabilities of transition between those three spirometric patterns. AB - Low FVC is the most frequent abnormal spirometric pattern in the WTC workers. Substantial stationary probabilities of stability (0.88) were observed for normal, and less so for low FVC (0.73) and obstructive (0.65) pattern. At least 80 % of the observed transitions involved the normal and low FVC patterns, and both higher WTC exposure intensity (early arrival at the site), and body mass index (BMI) were predictors of transitions to low FVC in this cohort. AB - Low FVC is relatively stable, and both WTC exposure intensity and BMI are independently and significantly associated with transitions to it. Transitions to obstruction are generally infrequent among the WTC workers and have greater instability. AB - Author manuscript AN - cdc:261390 C4 - PMC13197207 DO - https://doi.org/10.1016/j.rmed.2025.108170 J2 - Respiratory Medicine KW - Occupational Exposure KW - Longitudinal Studies KW - Female KW - Emergency Responders KW - Vital Capacity KW - Forced Expiratory Volume KW - Occupational Diseases KW - Cohort Studies KW - Body Mass Index KW - Male KW - Rescue Work KW - Humans KW - Middle Aged KW - Spirometry KW - September 11 Terrorist Attacks KW - Adult KW - Occupational medicine KW - Occupational health KW - Inhalation injury KW - Chronic obstructive pulmonary disease KW - Asthma KW - Cohort study KW - World Trade Center attack KW - 2001 KW - Humans KW - Spirometry KW - September 11 Terrorist Attacks KW - Male KW - Female KW - Adult KW - Occupational Exposure KW - Longitudinal Studies KW - Middle Aged KW - Forced Expiratory Volume KW - Vital Capacity KW - Body Mass Index KW - Rescue Work KW - Cohort Studies KW - Emergency Responders KW - Occupational Diseases LA - eng PY - 2025 T2 - Respiratory Medicine T2 - Respiratory Medicine, 2025, v. 244 TI - Spirometric Pattern Transitions in a World Trade Center Occupational Cohort on Longitudinal Surveillance. VL - 244 UR - https://stacks.cdc.gov/view/cdc/261390 ER -
Reach of An Occupational Health and Safety Program to Improve Sleep and Fatigue Among Nurses.

Hittle, Beverly M. ;

Guerin, Rebecca

October 2025 | Western Journal of Nursing Research, 2025, v. 47, no. 10

Training and education may benefit nurses whose nonstandard work hours put them at risk of poor sleep, fatigue, and ensuing adverse health and safety outcomes. The National Institute for Occupational Safety and Health (NIOSH) published "Training for Nurses on Shift Work and Long Work Hours" in 2015 as a free online resource which remains one of the ...

10/09/2026

Supporting Files

Title : Reach of An Occupational Health and Safety Program to Improve Sleep and Fatigue Among Nurses. Personal Author(s) : Hittle, Beverly M.;Guerin, Rebecca;Wong, Imelda S.; Published Date : October 2025 Pages in Document : 932-941 (18 pdf pages) Source : Western Journal of Nursing Research, 2025, v. 47, no. 10 DOI : https://doi.org/10.1177/01939459251340273 Journal Title : Western Journal of Nursing Research
Hittle, B. M., Guerin, R., & Wong, I. S. (2025). Reach of An Occupational Health and Safety Program to Improve Sleep and Fatigue Among Nurses. Western Journal of Nursing Research, 47(10). https://doi.org/10.1177/01939459251340273

Hittle, Beverly M., Rebecca Guerin, and Imelda S. Wong. "Reach of An Occupational Health and Safety Program to Improve Sleep and Fatigue Among Nurses." Western Journal of Nursing Research 47, no. 10 (2025). https://doi.org/10.1177/01939459251340273.

Hittle, Beverly M., et al. "Reach of An Occupational Health and Safety Program to Improve Sleep and Fatigue Among Nurses." Western Journal of Nursing Research, vol. 47, no. 10, 2025. Stacks. https://doi.org/10.1177/01939459251340273.
Export RIS Citation Information. TY - Journal Article AU - Hittle, Beverly M. AU - Guerin, Rebecca AU - Wong, Imelda S. AB - Training and education may benefit nurses whose nonstandard work hours put them at risk of poor sleep, fatigue, and ensuing adverse health and safety outcomes. The National Institute for Occupational Safety and Health (NIOSH) published "Training for Nurses on Shift Work and Long Work Hours" in 2015 as a free online resource which remains one of the few trainings available on this topic. However, the extent to which nurses have completed the program and the characteristics of current learners have not been examined. AB - We aimed to describe the potential reach of the NIOSH Training for Nurses between May 2015 through December 2020. AB - Data were obtained on learners who received continuing education credits upon completion of the NIOSH Training for Nurses. We applied a widely used implementation and evaluation framework, RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance), to describe the potential reach of the nurses' training and provide descriptive statistics of learners. AB - From 2015 to 2020, 7899 learners from different occupations received continuing education credits for completing the training. Approximately 60% of learners were nurses and 30% were students. Among nurses, most were Registered Nurses (93%), with few Licensed Practical Nurses (6%) and Advanced Practice Nurses (2%). In 2020, the number of learners who were nurses represented only 0.09% of all licensed US nurses. AB - A renewed dissemination plan may help extend training reach to the larger population of licensed US nurses. The NIOSH training remains a seminal, freely available, online resource for nurses, filling a critical gap in training to manage work-related fatigue. AB - Author manuscript AN - cdc:261389 C4 - PMC13353418 DO - https://doi.org/10.1177/01939459251340273 IS - 10 J2 - Western Journal of Nursing Research KW - Sleep KW - Female KW - Fatigue KW - Male KW - Humans KW - National Institute for Occupational Safety and Health, U.S. KW - Occupational Health KW - Nurses KW - Adult KW - United States KW - nurses KW - fatigue KW - fatigue mitigation KW - long work hours KW - shift work KW - sleep hygiene KW - sleep training KW - Humans KW - Fatigue KW - United States KW - Occupational Health KW - National Institute for Occupational Safety and Health, U.S. KW - Nurses KW - Sleep KW - Female KW - Adult KW - Male LA - eng PY - 2025 T2 - Western Journal of Nursing Research T2 - Western Journal of Nursing Research, 2025, v. 47, no. 10 TI - Reach of An Occupational Health and Safety Program to Improve Sleep and Fatigue Among Nurses. VL - 47 UR - https://stacks.cdc.gov/view/cdc/261389 ER -
Self-management For People With Epilepsy and a History of Negative Health Events (SMART): a Randomized Controlled Effectiveness Trial.

Sajatovic, Martha ;

Ghearing, Gena R.

October 2025 | Epilepsy & Behavior : E&B, 2025, v. 171

This 2-site, 6-month randomized controlled trial of an epilepsy self-management (ESM) curriculum (SMART) vs. 6-month waitlist (WL) control assessed effects on epilepsy outcomes in 160 people with epilepsy (PWE).PWE had at least 1 negative health event (NHE) defined as a seizure, emergency department visit, hospitalization or self-harm attempt in th ...

10/09/2026

Supporting Files

Title : Self-management For People With Epilepsy and a History of Negative Health Events (SMART): a Randomized Controlled Effectiveness Trial. Personal Author(s) : Sajatovic, Martha;Ghearing, Gena R.;Tyrrell, Maegan;Black, Jessica;Krehel-Montgomery, Jacqueline;Barigye, Richard;Yala, Joy;Adeniyi, Clara;Privitera, Michael;Rossi, Marvin A.;Briggs, Farren; Published Date : October 2025 Pages in Document : 110495 (21 pdf pages) Source : Epilepsy & Behavior : E&B, 2025, v. 171 DOI : https://doi.org/10.1016/j.yebeh.2025.110495 Journal Title : Epilepsy & Behavior : E&B
Sajatovic, M., Ghearing, G. R., Tyrrell, M., Black, J., Krehel-Montgomery, J., Barigye, R., Yala, J., Adeniyi, C., Privitera, M., Rossi, M. A., & Briggs, F. (2025). Self-management For People With Epilepsy and a History of Negative Health Events (SMART): a Randomized Controlled Effectiveness Trial. Epilepsy & Behavior : E&B, 171. https://doi.org/10.1016/j.yebeh.2025.110495

Sajatovic, Martha, Gena R. Ghearing, Maegan Tyrrell, Jessica Black, Jacqueline Krehel-Montgomery, Richard Barigye, and Joy Yala, et al.. "Self-management For People With Epilepsy and a History of Negative Health Events (SMART): a Randomized Controlled Effectiveness Trial." Epilepsy & Behavior : E&B 171 (2025). https://doi.org/10.1016/j.yebeh.2025.110495.

Sajatovic, Martha, et al. "Self-management For People With Epilepsy and a History of Negative Health Events (SMART): a Randomized Controlled Effectiveness Trial." Epilepsy & Behavior : E&B, vol. 171, 2025. Stacks. https://doi.org/10.1016/j.yebeh.2025.110495.
Export RIS Citation Information. TY - Journal Article AU - Sajatovic, Martha AU - Ghearing, Gena R. AU - Tyrrell, Maegan AU - Black, Jessica AU - Krehel-Montgomery, Jacqueline AU - Barigye, Richard AU - Yala, Joy AU - Adeniyi, Clara AU - Privitera, Michael AU - Rossi, Marvin A. AU - Briggs, Farren AB - This 2-site, 6-month randomized controlled trial of an epilepsy self-management (ESM) curriculum (SMART) vs. 6-month waitlist (WL) control assessed effects on epilepsy outcomes in 160 people with epilepsy (PWE). AB - PWE had at least 1 negative health event (NHE) defined as a seizure, emergency department visit, hospitalization or self-harm attempt in the last 6 months. Primary outcomes were differences in proportions of PWE with reductions in NHEs from baseline to 6 months follow up and change in NHE/seizure counts between SMART and WL. Secondary outcomes included the Patient Health Questionnaire (PHQ-9), 36-Item Short Form Survey (SF-36), Quality of Life in Epilepsy (QOLIE-31), Epilepsy Self-Management Scale (ESMS), Epilepsy Stigma Scale (ESS), Multidimensional Scale of Perceived Social Support (MSPSS) and Epilepsy Self-Efficacy Scale (ESES). AB - Mean age was 39.4 (SD 12.2), 66.9 % (N = 107) women, and 31 % (N = 50) rural. Mean PHQ-9 of 10.5 (SD 7) suggested mild/moderate depression. Seizures were the most common NHE with mean baseline past 6-month seizure count of 20.6 (SD 41.0). SMART was significantly associated with a 2-fold increase in odds of having at least 10-30 % improvement in NHEs vs. WL (p < 0.05). SMART was associated with significant seizure reduction (p < 0.05), significantly improved PHQ-9 (p = 0.014), QOLIE-31 seizure worry (p = <0.001) and social functioning (p = 0.021), ESES (p = 0.046) and ESMS (p < 0.001). AB - Compared to WL, SMART participants had improvement in NHEs and seizures, depressive symptoms, self-management competency and self-efficacy and selected elements of quality of life. Inclusion of effective ESMs into a comprehensive care of model for PWE may be warranted. AB - Author manuscript AN - cdc:261388 C4 - PMC13482782 DO - https://doi.org/10.1016/j.yebeh.2025.110495 J2 - Epilepsy & Behavior : E&B KW - Self Efficacy KW - Female KW - Treatment Outcome KW - Social Stigma KW - Social Support KW - Self-Management KW - Surveys and Questionnaires KW - Epilepsy KW - Quality of Life KW - Male KW - Middle Aged KW - Humans KW - Adult KW - epilepsy KW - seizures KW - stigma KW - depression KW - quality of life KW - Adult KW - Female KW - Humans KW - Male KW - Middle Aged KW - Epilepsy KW - Quality of Life KW - Self Efficacy KW - Self-Management KW - Social Stigma KW - Social Support KW - Surveys and Questionnaires KW - Treatment Outcome LA - eng PY - 2025 T2 - Epilepsy & Behavior : E&B T2 - Epilepsy & Behavior : E&B, 2025, v. 171 TI - Self-management For People With Epilepsy and a History of Negative Health Events (SMART): a Randomized Controlled Effectiveness Trial. VL - 171 UR - https://stacks.cdc.gov/view/cdc/261388 ER -
Smooth Muscle Relaxants For Intrauterine Device Placement: a Systematic Review.

Snyder, Emily M. ;

Krishna, Gopika

July 2026 | Contraception, 2026, v. 159

To systematically review evidence on whether medications with smooth muscle relaxant properties improve patient and provider outcomes for intrauterine device (IUD) placement.We searched multiple databases through August 2022 for randomized clinical trials assessing smooth muscle relaxants for IUD placement. Primary outcomes were pain experienced wi ...

10/09/2026

Supporting Files

Title : Smooth Muscle Relaxants For Intrauterine Device Placement: a Systematic Review. Personal Author(s) : Snyder, Emily M.;Krishna, Gopika;Zapata, Lauren B.;Nguyen, Antoinette T.;Whiteman, Maura K.;Curtis, Kathryn M.; Published Date : July 2026 Pages in Document : 110971 (15 pdf pages) Source : Contraception, 2026, v. 159 DOI : https://doi.org/10.1016/j.contraception.2025.110971 Journal Title : Contraception
Snyder, E. M., Krishna, G., Zapata, L. B., Nguyen, A. T., Whiteman, M. K., & Curtis, K. M. (2026). Smooth Muscle Relaxants For Intrauterine Device Placement: a Systematic Review. Contraception, 159. https://doi.org/10.1016/j.contraception.2025.110971

Snyder, Emily M., Gopika Krishna, Lauren B. Zapata, Antoinette T. Nguyen, Maura K. Whiteman, and Kathryn M. Curtis. "Smooth Muscle Relaxants For Intrauterine Device Placement: a Systematic Review." Contraception 159 (2026). https://doi.org/10.1016/j.contraception.2025.110971.

Snyder, Emily M., et al. "Smooth Muscle Relaxants For Intrauterine Device Placement: a Systematic Review." Contraception, vol. 159, 2026. Stacks. https://doi.org/10.1016/j.contraception.2025.110971.
Export RIS Citation Information. TY - Journal Article AU - Snyder, Emily M. AU - Krishna, Gopika AU - Zapata, Lauren B. AU - Nguyen, Antoinette T. AU - Whiteman, Maura K. AU - Curtis, Kathryn M. AB - To systematically review evidence on whether medications with smooth muscle relaxant properties improve patient and provider outcomes for intrauterine device (IUD) placement. AB - We searched multiple databases through August 2022 for randomized clinical trials assessing smooth muscle relaxants for IUD placement. Primary outcomes were pain experienced with IUD placement, provider ease of placement, need for adjunctive placement measures, placement success, patient satisfaction with procedure, medication side effects occurring before clinic discharge, and adverse events occurring before clinic discharge. We extracted data from included articles, assessed risk of bias for each trial, narratively summarized results, and determined certainty of evidence for all outcomes. AB - Five placebo-controlled trials met inclusion criteria; four trials had low risk of bias and one had moderate risk. Two trials of topical nitroprusside gel or nitroglycerin ointment found no differences in patient pain, provider ease of placement, patient satisfaction, placement success, side effects, or adverse events. One trial suggested that drotaverine plus mefenamic acid reduced patient pain but did not improve placement success. Two trials suggested that isonicotinic acid hydrazide reduced patient pain, improved provider ease of placement and patient satisfaction, reduced need for analgesia and for cervical dilation (in one trial) and did not increase side effects; neither trial reported improved placement success. AB - Evidence on smooth muscle relaxants for IUD placement remains sparse with inconsistent findings across specific medications. Certainty of evidence for all outcomes was low for topical nitroprusside gel and nitroglycerin ointment, very low for drotaverine plus mefenamic acid, and mostly high for isonicotinic acid hydrazide. AB - Before IUD placement, healthcare providers can counsel patients on the potential for pain during placement and options for pain management. However, more evidence is needed on specific smooth muscle relaxants to determine their effectiveness as an intervention for IUD placement. AB - Author manuscript AN - cdc:261387 C4 - PMC12326637 DO - https://doi.org/10.1016/j.contraception.2025.110971 J2 - Contraception KW - Muscle, Smooth KW - Contraception KW - Intrauterine Devices KW - Systematic review KW - Contraception KW - Intrauterine device KW - Systematic review KW - Contraception KW - Intrauterine Devices KW - Systematic review KW - Muscle, Smooth LA - eng PY - 2026 T2 - Contraception T2 - Contraception, 2026, v. 159 TI - Smooth Muscle Relaxants For Intrauterine Device Placement: a Systematic Review. VL - 159 UR - https://stacks.cdc.gov/view/cdc/261387 ER -
Safety of NOPV2 Administered During a Supplementary Immunisation Activity in Uganda, 2022: Data Triangulation From a Prospective Cohort Event Monitoring Programme and Vaccine Safety Surveillance Reports.

Longley, Ashley T ;

Nsubuga, Fred

July 2025 | The Lancet. Global Health, 2025, v. 13, no. 7

In November, 2020, WHO authorised novel oral polio vaccine type 2 (nOPV2) use under Emergency Use Listing in response to outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2). Although no concerns were identified in nOPV2 trials, the Global Advisory Committee on Vaccine Safety requested more extensive vaccine safety data during emerge ...

10/09/2026

Supporting Files

Title : Safety of NOPV2 Administered During a Supplementary Immunisation Activity in Uganda, 2022: Data Triangulation From a Prospective Cohort Event Monitoring Programme and Vaccine Safety Surveillance Reports. Personal Author(s) : Longley, Ashley T;Nsubuga, Fred;Gilani, Zunera;Tobolowsky, Farrell A;Kisakye, Annet;Greene, Sharon A;Ampeire, Immaculate;Ssennono, Vincent Fred;Gyasi, Samuel Ofori;Ntale, Ismail;Bammeke, Philip;Stewart, Brock;Ndagije, Helen Byomire;Kyabayinze, Daniel J;Gidudu, Jane F; Published Date : July 2025 Pages in Document : e1213-e1220 (18 pdf pages) Source : The Lancet. Global Health, 2025, v. 13, no. 7 DOI : https://doi.org/10.1016/S2214-109X(25)00110-X Journal Title : The Lancet. Global Health
Longley, A. T., Nsubuga, F., Gilani, Z., Tobolowsky, F. A., Kisakye, A., Greene, S. A., Ampeire, I., Ssennono, V. F., Gyasi, S. O., Ntale, I., Bammeke, P., Stewart, B., Ndagije, H. B., Kyabayinze, D. J., & Gidudu, J. F. (2025). Safety of NOPV2 Administered During a Supplementary Immunisation Activity in Uganda, 2022: Data Triangulation From a Prospective Cohort Event Monitoring Programme and Vaccine Safety Surveillance Reports. The Lancet. Global Health, 13(7). https://doi.org/10.1016/S2214-109X(25)00110-X

Longley, Ashley T, Fred Nsubuga, Zunera Gilani, Farrell A Tobolowsky, Annet Kisakye, Sharon A Greene, and Immaculate Ampeire, et al.. "Safety of NOPV2 Administered During a Supplementary Immunisation Activity in Uganda, 2022: Data Triangulation From a Prospective Cohort Event Monitoring Programme and Vaccine Safety Surveillance Reports." The Lancet. Global Health 13, no. 7 (2025). https://doi.org/10.1016/S2214-109X(25)00110-X.

Longley, Ashley T, et al. "Safety of NOPV2 Administered During a Supplementary Immunisation Activity in Uganda, 2022: Data Triangulation From a Prospective Cohort Event Monitoring Programme and Vaccine Safety Surveillance Reports." The Lancet. Global Health, vol. 13, no. 7, 2025. Stacks. https://doi.org/10.1016/S2214-109X(25)00110-X.
Export RIS Citation Information. TY - Journal Article AU - Longley, Ashley T AU - Nsubuga, Fred AU - Gilani, Zunera AU - Tobolowsky, Farrell A AU - Kisakye, Annet AU - Greene, Sharon A AU - Ampeire, Immaculate AU - Ssennono, Vincent Fred AU - Gyasi, Samuel Ofori AU - Ntale, Ismail AU - Bammeke, Philip AU - Stewart, Brock AU - Ndagije, Helen Byomire AU - Kyabayinze, Daniel J AU - Gidudu, Jane F AB - In November, 2020, WHO authorised novel oral polio vaccine type 2 (nOPV2) use under Emergency Use Listing in response to outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2). Although no concerns were identified in nOPV2 trials, the Global Advisory Committee on Vaccine Safety requested more extensive vaccine safety data during emergency use. The Uganda Ministry of Health declared a cVDPV2 outbreak in 2021 and responded with an nOPV2 campaign in January, 2022. More than 9 million children aged 0-59 months were vaccinated, providing an opportunity to generate robust safety data. AB - We monitored the safety of nOPV2 for 42 days post-vaccination using: routine passive surveillance for adverse events following immunisation (AEFI); ongoing acute flaccid paralysis (AFP) surveillance; active, hospital-based surveillance for pre-specified adverse events of special interest (AESI); and active, cohort event monitoring. AFP cases were reviewed by the National Polio Expert Committee. Serious AEFI and all AESI and AFP cases with nOPV2 receipt underwent causality assessment by the National AEFI Committee. AB - Across surveillance systems, 1128 children vaccinated with nOPV2 experienced one or more AEFI: 43 children identified through passive surveillance, 128 suspected AFP cases, five AESI cases, and 952 children with reported AEFI through cohort event monitoring. Overall, 109 adverse events were considered serious; six (fever, gastroenteritis (n=3), acute disseminated encephalomyelitis, and encephalitis) were determined by the National AEFI Committee to be consistent with causal association to immunisation with nOPV2. No cases of vaccine-associated paralytic poliomyelitis were detected. One death was detected, considered inconsistent with causal association to immunisation with nOPV2, per the National AEFI Committee. AB - No new safety concerns were identified with nOPV2 use in Uganda following a national vaccination campaign, providing valuable data that informed WHO prequalification and product licensure. AB - Centers for Disease Control and Prevention. AB - For the French translation of the abstract see Supplementary Materials section. AB - Author manuscript AN - cdc:261386 C4 - PMC12213129 DO - https://doi.org/10.1016/S2214-109X(25)00110-X IS - 7 J2 - The Lancet. Global Health KW - Adverse Drug Reaction Reporting Systems KW - Female KW - Infant KW - Immunization Programs KW - Male KW - Prospective Studies KW - Humans KW - Child, Preschool KW - Infant, Newborn KW - Poliomyelitis KW - Poliovirus Vaccine, Oral KW - Humans KW - Infant KW - Child, Preschool KW - Poliomyelitis KW - Poliovirus Vaccine, Oral KW - Prospective Studies KW - Female KW - Infant, Newborn KW - Adverse Drug Reaction Reporting Systems KW - Male KW - Immunization Programs LA - eng PY - 2025 T2 - The Lancet. Global Health T2 - The Lancet. Global Health, 2025, v. 13, no. 7 TI - Safety of NOPV2 Administered During a Supplementary Immunisation Activity in Uganda, 2022: Data Triangulation From a Prospective Cohort Event Monitoring Programme and Vaccine Safety Surveillance Reports. VL - 13 UR - https://stacks.cdc.gov/view/cdc/261386 ER -
Influenza Vaccination During Early Pregnancy and Risk of Major Birth Defects, US Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019.

Malange, Veronica ;

Mohaissen, Tasnim

June 2025 | Vaccine, 2025, v. 59

Studies of influenza vaccination during pregnancy and major birth defects generally provide reassuring findings. To maintain public confidence, it is important to continue evaluating the safety of maternal vaccination using well characterized, population-based data. This study extended previous research to examine associations between maternal infl ...

10/09/2026

Supporting Files

Title : Influenza Vaccination During Early Pregnancy and Risk of Major Birth Defects, US Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019. Personal Author(s) : Malange, Veronica;Mohaissen, Tasnim;Conway, Kristin M.;Rhoads, Anthony;Morris, Joan K.;Ailes, Elizabeth C.;Hedley, Paula L.;Cragan, Janet D.;Nestoridi, Eirini;Papadopoulos, Eleni A.;Scholz, Thomas D.;Sidhu, Alpa;Christiansen, Michael;Romitti, Paul A.; Published Date : June 2025 Pages in Document : 127297 (21 pdf pages) Source : Vaccine, 2025, v. 59 DOI : https://doi.org/10.1016/j.vaccine.2025.127297 Journal Title : Vaccine
Malange, V., Mohaissen, T., Conway, K. M., Rhoads, A., Morris, J. K., Ailes, E. C., Hedley, P. L., Cragan, J. D., Nestoridi, E., Papadopoulos, E. A., Scholz, T. D., Sidhu, A., Christiansen, M., & Romitti, P. A. (2025). Influenza Vaccination During Early Pregnancy and Risk of Major Birth Defects, US Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019. Vaccine, 59. https://doi.org/10.1016/j.vaccine.2025.127297

Malange, Veronica, Tasnim Mohaissen, Kristin M. Conway, Anthony Rhoads, Joan K. Morris, Elizabeth C. Ailes, and Paula L. Hedley, et al.. "Influenza Vaccination During Early Pregnancy and Risk of Major Birth Defects, US Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019." Vaccine 59 (2025). https://doi.org/10.1016/j.vaccine.2025.127297.

Malange, Veronica, et al. "Influenza Vaccination During Early Pregnancy and Risk of Major Birth Defects, US Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019." Vaccine, vol. 59, 2025. Stacks. https://doi.org/10.1016/j.vaccine.2025.127297.
Export RIS Citation Information. TY - Journal Article AU - Malange, Veronica AU - Mohaissen, Tasnim AU - Conway, Kristin M. AU - Rhoads, Anthony AU - Morris, Joan K. AU - Ailes, Elizabeth C. AU - Hedley, Paula L. AU - Cragan, Janet D. AU - Nestoridi, Eirini AU - Papadopoulos, Eleni A. AU - Scholz, Thomas D. AU - Sidhu, Alpa AU - Christiansen, Michael AU - Romitti, Paul A. AB - Studies of influenza vaccination during pregnancy and major birth defects generally provide reassuring findings. To maintain public confidence, it is important to continue evaluating the safety of maternal vaccination using well characterized, population-based data. This study extended previous research to examine associations between maternal influenza vaccination and selected birth defects using data from the Birth Defects Study To Evaluate Pregnancy exposureS, a US, multisite case-control study. AB - Mothers of case children (diagnosed with a birth defect) and control children (without a birth defect diagnosis) were identified from population-based birth defect surveillance programs and recruited to complete a telephone interview. Data from 2675 case and 1575 control mothers (participants) with deliveries during 2014-2019 were analyzed. Influenza vaccination exposure during the critical exposure period (one month before pregnancy through the first pregnancy month [B1P1] for spina bifida or through the third pregnancy month [B1P3] for other selected birth defects) was assessed controlling for several participant covariates. Logistic regression with propensity score adjustment was used to estimate adjusted odds ratios (aORs) and 95 % confidence intervals (CIs). Several secondary analyses were conducted. A probabilistic bias analysis examined the effect of exposure misclassification. AB - The aOR observed between B1P1 influenza vaccination exposure and spina bifida was 0.9 (95 % CI: 0.4-2.0). The aORs for B1P3 exposure and other selected birth defects examined ranged from 0.4 to 1.3, with 95 % CIs including the null except those for cleft lip ± cleft palate (aOR: 0.6; 95 % CI: 0.4-0.9) and gastroschisis (aOR: 0.4; 95 % CI: 0.2-0.7). Results from secondary analyses were similar to the primary analyses, and those from probabilistic bias analysis were similar to respective primary and secondary analyses. AB - Findings showed no statistically significant positive associations between influenza vaccination and the selected birth defects, supporting public health efforts to promote optimal vaccination coverage among pregnant women. AB - Author manuscript AN - cdc:261385 C4 - PMC12990147 DO - https://doi.org/10.1016/j.vaccine.2025.127297 J2 - Vaccine KW - Pregnancy KW - Pregnancy Complications, Infectious KW - Female KW - Vaccination KW - Case-Control Studies KW - Humans KW - Young Adult KW - Infant, Newborn KW - Influenza Vaccines KW - Adult KW - Influenza, Human KW - Congenital Abnormalities KW - Birth defects KW - Congenital abnormalities KW - Spina bifida KW - Influenza vaccines KW - Pregnancy KW - Humans KW - Female KW - Pregnancy KW - Influenza Vaccines KW - Congenital Abnormalities KW - Influenza, Human KW - Case-Control Studies KW - Adult KW - Vaccination KW - Young Adult KW - Pregnancy Complications, Infectious KW - Infant, Newborn LA - eng PY - 2025 T2 - Vaccine T2 - Vaccine, 2025, v. 59 TI - Influenza Vaccination During Early Pregnancy and Risk of Major Birth Defects, US Birth Defects Study to Evaluate Pregnancy ExposureS, 2014-2019. VL - 59 UR - https://stacks.cdc.gov/view/cdc/261385 ER -
Glycoprotein L-deleted Single-cycle Rhesus Cytomegalovirus Vectors Elicit MHC-E-restricted CD8+ T Cells That Protect Against SIV.

Hansen, Scott G. ;

Schell, John B.

May 2025 | Journal of Immunology (Baltimore, MD.: 1950), 2025, v. 214, no. 8

Strain 68-1 rhesus CMV (RhCMV) vectors induce immune responses that mediate early, complete replication arrest of SIV infection in ∼60% of vaccinated rhesus macaques (RMs). This unique efficacy depends on the ability of these vectors to elicit effector memory (EM)-biased CD8+ T cells recognizing SIV peptides presented by MHC-E, rather than MHC-Ia. ...

10/09/2026

Supporting Files

Title : Glycoprotein L-deleted Single-cycle Rhesus Cytomegalovirus Vectors Elicit MHC-E-restricted CD8+ T Cells That Protect Against SIV. Personal Author(s) : Hansen, Scott G.;Schell, John B.;Marshall, Emily E.;Ojha, Sohita;Feltham, Shana;Morrow, David;Hughes, Colette M.;Gilbride, Roxanne M.;Ford, Julia C.;Cleveland-Rubeor, Hilary C.;McArdle, Matthew R.;Whitmer, Travis;Barber-Axthelm, Aaron;Bochart, Rachelle;Smedley, Jeremy;Oswald, Kelli;Fast, Randy;Shoemaker, Rebecca;Kosmider, Ewelina;Edlefsen, Paul T.;Lifson, Jeffrey D.;Malouli, Daniel;Früh, Klaus;Picker, Louis J.; Published Date : May 2025 Pages in Document : 1969-1981 (25 pdf pages) Source : Journal of Immunology (Baltimore, MD.: 1950), 2025, v. 214, no. 8 DOI : https://doi.org/10.1093/jimmun/vkaf104 Journal Title : Journal of Immunology (Baltimore, MD.: 1950)
Hansen, S. G., Schell, J. B., Marshall, E. E., Ojha, S., Feltham, S., Morrow, D., Hughes, C. M., Gilbride, R. M., Ford, J. C., Cleveland-Rubeor, H. C., McArdle, M. R., Whitmer, T., Barber-Axthelm, A., Bochart, R., Smedley, J., Oswald, K., Fast, R., Shoemaker, R., Kosmider, E., ... Picker, L. J. (2025). Glycoprotein L-deleted Single-cycle Rhesus Cytomegalovirus Vectors Elicit MHC-E-restricted CD8+ T Cells That Protect Against SIV. Journal of Immunology (Baltimore, MD.: 1950), 214(8). https://doi.org/10.1093/jimmun/vkaf104

Hansen, Scott G., John B. Schell, Emily E. Marshall, Sohita Ojha, Shana Feltham, David Morrow, and Colette M. Hughes, et al.. "Glycoprotein L-deleted Single-cycle Rhesus Cytomegalovirus Vectors Elicit MHC-E-restricted CD8+ T Cells That Protect Against SIV." Journal of Immunology (Baltimore, MD.: 1950) 214, no. 8 (2025). https://doi.org/10.1093/jimmun/vkaf104.

Hansen, Scott G., et al. "Glycoprotein L-deleted Single-cycle Rhesus Cytomegalovirus Vectors Elicit MHC-E-restricted CD8+ T Cells That Protect Against SIV." Journal of Immunology (Baltimore, MD.: 1950), vol. 214, no. 8, 2025. Stacks. https://doi.org/10.1093/jimmun/vkaf104.
Export RIS Citation Information. TY - Journal Article AU - Hansen, Scott G. AU - Schell, John B. AU - Marshall, Emily E. AU - Ojha, Sohita AU - Feltham, Shana AU - Morrow, David AU - Hughes, Colette M. AU - Gilbride, Roxanne M. AU - Ford, Julia C. AU - Cleveland-Rubeor, Hilary C. AU - McArdle, Matthew R. AU - Whitmer, Travis AU - Barber-Axthelm, Aaron AU - Bochart, Rachelle AU - Smedley, Jeremy AU - Oswald, Kelli AU - Fast, Randy AU - Shoemaker, Rebecca AU - Kosmider, Ewelina AU - Edlefsen, Paul T. AU - Lifson, Jeffrey D. AU - Malouli, Daniel AU - Früh, Klaus AU - Picker, Louis J. AB - Strain 68-1 rhesus CMV (RhCMV) vectors induce immune responses that mediate early, complete replication arrest of SIV infection in ∼60% of vaccinated rhesus macaques (RMs). This unique efficacy depends on the ability of these vectors to elicit effector memory (EM)-biased CD8+ T cells recognizing SIV peptides presented by MHC-E, rather than MHC-Ia. These efficacious responses still occurred when spread of the 68-1 vector was impaired by deletion of the viral anti-host intrinsic immunity factor phosphoprotein 71 (pp71), but efficacy was lost with a more stringent attenuation strategy based on destabilization of Rh108, the ortholog of the essential human CMV (HCMV) transcription factor UL79 that is required for late viral gene expression. Although unable to produce infectious progeny (ie single-cycle infection), Rh108-deficient vectors elicited durable, high frequency, EM-biased, SIV-specific CD8+ T-cell responses in RMs, but these responses were MHC-Ia-restricted and therefore non-efficacious. Here, we tested a different single-cycle attenuation strategy based on deletion (Δ) of the glycoprotein L (gL) that is essential for viral entry but allows for late gene expression and viral assembly. ΔgL 68-1 RhCMV/SIV vectors, grown on gL-complementing fibroblasts, were robustly immunogenic at doses above 105 PFU, generating high frequency, EM-biased, SIV-specific CD8+ T-cell responses that were also unconventionally restricted, including the MHC-E restriction associated with efficacy. Indeed, these single-cycle vectors manifested replication arrest efficacy in 70% of vaccinated RMs, further linking MHC-E restriction with efficacy, and demonstrating that 68-1 RhCMV/SIV efficacy does not require vector dissemination within the host. AB - Author manuscript AN - cdc:261384 C4 - PMC12396747 DO - https://doi.org/10.1093/jimmun/vkaf104 IS - 8 J2 - Journal of Immunology (Baltimore, MD.: 1950) KW - Cytomegalovirus KW - CD8-Positive T-Lymphocytes KW - SAIDS Vaccines KW - Animals KW - Viral Envelope Proteins KW - Simian Immunodeficiency Virus KW - Simian Acquired Immunodeficiency Syndrome KW - Macaca mulatta KW - Humans KW - Genetic Vectors KW - Histocompatibility Antigens Class I KW - CD8 KW - + KW - T cells KW - CMV vectors KW - HIV vaccine KW - MHC-E KW - Animals KW - Macaca mulatta KW - CD8-Positive T-Lymphocytes KW - Cytomegalovirus KW - Simian Immunodeficiency Virus KW - Histocompatibility Antigens Class I KW - Genetic Vectors KW - Simian Acquired Immunodeficiency Syndrome KW - SAIDS Vaccines KW - Humans KW - Viral Envelope Proteins LA - eng PY - 2025 T2 - Journal of Immunology (Baltimore, MD.: 1950) T2 - Journal of Immunology (Baltimore, MD.: 1950), 2025, v. 214, no. 8 TI - Glycoprotein L-deleted Single-cycle Rhesus Cytomegalovirus Vectors Elicit MHC-E-restricted CD8+ T Cells That Protect Against SIV. VL - 214 UR - https://stacks.cdc.gov/view/cdc/261384 ER -
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE.

Hsia, Daniel S. ;

Younes, Naji

May 2025 | Diabetes Care, 2025, v. 48, no. 7

To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin.Intention-to-treat (ITT) (N = 5,047) and on-assigned-treatment (AT) (N = 4,830) d ...

10/09/2026

Supporting Files

Title : Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE. Personal Author(s) : Hsia, Daniel S.;Younes, Naji;Ghosh, Alokananda;Kazemi, Erin J.;Krause-Steinrauf, Heidi;Buse, John B.;Baker, Chelsea;Brown-Friday, Janet;Diaz, Elsa;Diner, Jamie;Groessl, Erik J.;Legowski, Elizabeth A.;Mariash, Cary N.;Waltje, Andrea H.;Wexler, Deborah J.;Martin, Catherine L.; Corporate Authors(s) : for the GRADE Research Group Published Date : May 2025 Pages in Document : 1288-1294 (15 pdf pages) Source : Diabetes Care, 2025, v. 48, no. 7 DOI : https://doi.org/10.2337/dc24-2839 Journal Title : Diabetes Care
Hsia, D. S., Younes, N., Ghosh, A., Kazemi, E. J., Krause-Steinrauf, H., Buse, J. B., Baker, C., Brown-Friday, J., Diaz, E., Diner, J., Groessl, E. J., Legowski, E. A., Mariash, C. N., Waltje, A. H., Wexler, D. J., & Martin, C. L. (2025). Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE. Diabetes Care, 48(7). https://doi.org/10.2337/dc24-2839

Hsia, Daniel S., Naji Younes, Alokananda Ghosh, Erin J. Kazemi, Heidi Krause-Steinrauf, John B. Buse, and Chelsea Baker, et al.. "Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE." Diabetes Care 48, no. 7 (2025). https://doi.org/10.2337/dc24-2839.

Hsia, Daniel S., et al. "Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE." Diabetes Care, vol. 48, no. 7, 2025. Stacks. https://doi.org/10.2337/dc24-2839.
Export RIS Citation Information. TY - Journal Article AU - Hsia, Daniel S. AU - Younes, Naji AU - Ghosh, Alokananda AU - Kazemi, Erin J. AU - Krause-Steinrauf, Heidi AU - Buse, John B. AU - Baker, Chelsea AU - Brown-Friday, Janet AU - Diaz, Elsa AU - Diner, Jamie AU - Groessl, Erik J. AU - Legowski, Elizabeth A. AU - Mariash, Cary N. AU - Waltje, Andrea H. AU - Wexler, Deborah J. AU - Martin, Catherine L. A2 - for the GRADE Research Group AB - To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin. AB - Intention-to-treat (ITT) (N = 5,047) and on-assigned-treatment (AT) (N = 4,830) data sets were used. Baseline differences between those hospitalized versus those not hospitalized were assessed. Kaplan-Meier analysis was used to determine incidence for time to first hospitalization, and log-rank tests were used to determine treatment group differences. Time-to-event analyses were used to examine factors affecting subsequent hospitalization risk. AB - During GRADE, 1,636 participants (32.4%) were hospitalized at least once and 751 (14.9%) were hospitalized more than once. Hospitalized participants were older, less likely to be Hispanic, more likely to be White, and more likely to have a history of hypertension and had higher baseline BMI. There were no treatment group differences in incidence for time to first hospitalization in the ITT data set (P = 0.148), but a reduced hazard rate was observed for those taking liraglutide versus those taking glimepiride in the AT data set (hazard ratio 0.78 [95% CI 0.66, 0.92]; P = 0.022). Factors increasing the risk for subsequent hospitalizations included meeting the secondary outcome (HbA1c >7.5%, confirmed), each prior hospitalization, and change from assigned treatment (29%, 41%, and 56% increase in risk, respectively). Assignment to liraglutide versus glimepiride reduced this risk by 13%. AB - Hospitalizations were common in GRADE, and rates were nearly identical across treatment groups. The small, but significant, reduction in risk for subsequent hospitalizations among participants assigned to liraglutide versus glimepiride may influence treatment decisions in populations similar to GRADE participants. AB - Author manuscript AN - cdc:261383 C4 - PMC12178615 DO - https://doi.org/10.2337/dc24-2839 IS - 7 J2 - Diabetes Care KW - Female KW - Sulfonylurea Compounds KW - Sitagliptin Phosphate KW - Metformin KW - Aged KW - Diabetes Mellitus, Type 2 KW - Liraglutide KW - Hospitalization KW - Male KW - Hypoglycemic Agents KW - Middle Aged KW - Humans KW - Insulin Glargine KW - Blood Glucose KW - diabetes treatment KW - hospitalizations KW - serious adverse events KW - Aged KW - Female KW - Humans KW - Male KW - Middle Aged KW - Blood Glucose KW - Diabetes Mellitus, Type 2 KW - Hospitalization KW - Hypoglycemic Agents KW - Insulin Glargine KW - Liraglutide KW - Metformin KW - Sitagliptin Phosphate KW - Sulfonylurea Compounds LA - eng PY - 2025 T2 - Diabetes Care T2 - Diabetes Care, 2025, v. 48, no. 7 TI - Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE. VL - 48 UR - https://stacks.cdc.gov/view/cdc/261383 ER -
Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment.

Roberts, Sarah T. ;

Browne, Erica N.

August 2025 | AIDS (London, England), 2025, v. 39, no. 10

Longer-acting preexposure prophylaxis (LA-PrEP) products have potential to increase PrEP uptake and continuation. This study sought to elicit preferences for LA-PrEP product and delivery program characteristics among populations disproportionately impacted by HIV to identify factors important to adoption and anticipate potential use challenges.Cros ...

10/09/2026

Supporting Files

Title : Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment. Personal Author(s) : Roberts, Sarah T.;Browne, Erica N.;Denson, Damian;Moore, Emily;Mungo, Jackie;Mancuso, Noah;Diaz, Miranda;Patel, Rupa;Kourtis, Athena P.;Minnis, Alexandra M.;Hoover, Karen W.; Published Date : August 2025 Pages in Document : 1364-1374 (18 pdf pages) Source : AIDS (London, England), 2025, v. 39, no. 10 DOI : https://doi.org/10.1097/QAD.0000000000004247 Journal Title : AIDS (London, England)
Roberts, S. T., Browne, E. N., Denson, D., Moore, E., Mungo, J., Mancuso, N., Diaz, M., Patel, R., Kourtis, A. P., Minnis, A. M., & Hoover, K. W. (2025). Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment. AIDS (London, England), 39(10). https://doi.org/10.1097/QAD.0000000000004247

Roberts, Sarah T., Erica N. Browne, Damian Denson, Emily Moore, Jackie Mungo, Noah Mancuso, and Miranda Diaz, et al.. "Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment." AIDS (London, England) 39, no. 10 (2025). https://doi.org/10.1097/QAD.0000000000004247.

Roberts, Sarah T., et al. "Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment." AIDS (London, England), vol. 39, no. 10, 2025. Stacks. https://doi.org/10.1097/QAD.0000000000004247.
Export RIS Citation Information. TY - Journal Article AU - Roberts, Sarah T. AU - Browne, Erica N. AU - Denson, Damian AU - Moore, Emily AU - Mungo, Jackie AU - Mancuso, Noah AU - Diaz, Miranda AU - Patel, Rupa AU - Kourtis, Athena P. AU - Minnis, Alexandra M. AU - Hoover, Karen W. AB - Longer-acting preexposure prophylaxis (LA-PrEP) products have potential to increase PrEP uptake and continuation. This study sought to elicit preferences for LA-PrEP product and delivery program characteristics among populations disproportionately impacted by HIV to identify factors important to adoption and anticipate potential use challenges. AB - Cross-sectional, online discrete choice experiment. AB - We recruited 940 men who have sex with men (MSM), people who inject drugs (PWID), and Black heterosexual men and women (BHMW) with PrEP indications. In a series of 10 tasks, participants chose between two hypothetical LA-PrEP options composed of 5 attributes (product type, side effects, clinic type, appointment duration, cost), or neither (their current HIV prevention method). Analysis used random-parameters logit models. AB - Respondents chose an LA-PrEP method over their current HIV prevention option in 96.8% of tasks. Cost was the most important determinant of LA-PrEP choice for all populations (relative importance [RI] of 10]. Side effects and product type were 1/3 to 1/2 as important as cost (RI 3.5-5.1). MSM and PWID most preferred the 12-month implant followed by semiannual dual injections and least preferred the monthly oral pill and 2-month single injection. BHMW most preferred the monthly pill and semiannual injections and least preferred the 12-month implant and 2-month injection. Clinic type and appointment duration had minimal influence (RI 0.1-2.1). AB - Results suggest high demand for LA-PrEP among populations with disproportionately high HIV incidence. To facilitate use, programs should offer a range of LA-PrEP products, minimize out-of-pocket costs, and counsel on side effects. AB - Author manuscript AN - cdc:261382 C4 - PMC12459700 DO - https://doi.org/10.1097/QAD.0000000000004247 IS - 10 J2 - AIDS (London, England) KW - Female KW - Anti-HIV Agents KW - Young Adult KW - Homosexuality, Male KW - Pre-Exposure Prophylaxis KW - Cross-Sectional Studies KW - Patient Preference KW - Chemoprevention KW - Male KW - Middle Aged KW - Humans KW - Adult KW - Choice Behavior KW - Disease Transmission, Infectious KW - HIV Infections KW - black heterosexual men and women KW - discrete choice experiment KW - HIV prevention KW - longer-acting preexposure prophylaxis KW - men who have sex with men KW - people who inject drugs KW - Humans KW - Pre-Exposure Prophylaxis KW - HIV Infections KW - Male KW - Cross-Sectional Studies KW - Female KW - Adult KW - Middle Aged KW - Young Adult KW - Anti-HIV Agents KW - Patient Preference KW - Disease Transmission, Infectious KW - Homosexuality, Male KW - Choice Behavior KW - Chemoprevention LA - eng PY - 2025 T2 - AIDS (London, England) T2 - AIDS (London, England), 2025, v. 39, no. 10 TI - Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment. VL - 39 UR - https://stacks.cdc.gov/view/cdc/261382 ER -
Intrinsic Immunogenicity is a Major Determinant of Type-specific Responses in SARS-CoV-2 Infections.

Quirk, Grace E. ;

Schoenle, Marta V.

June 2025 | Nature Immunology, 2025, v. 26, no. 6

Few type-specific antibodies that recognize drifted epitopes are made during post-vaccination exposures to SARS-CoV-2 variants, perhaps due to suppression by previous immunity. We compared type-specific B cell responses in unvaccinated and vaccinated individuals with Delta and Omicron BA.1 SARS-CoV-2 variant infections. For both Delta, which is ant ...

10/09/2026

Supporting Files

Title : Intrinsic Immunogenicity is a Major Determinant of Type-specific Responses in SARS-CoV-2 Infections. Personal Author(s) : Quirk, Grace E.;Schoenle, Marta V.;Peyton, Kameron L.;Uhrlaub, Jennifer L.;Lau, Branden;Liang, Chieh-Yu;Burgess, Jefferey L.;Ellingson, Katherine;Beitel, Shawn;Romine, James;Lutrick, Karen;Fowlkes, Ashley;Britton, Amadea;Tyner, Harmony L.;Caban-Martinez, Alberto J.;Naleway, Allison;Gaglani, Manjusha;Yoon, Sarang;Edwards, Laura J.;Olsho, Lauren;Dake, Michael;Valdez, Riccardo;Gordon, Aubree;Diamond, Michael S.;LaFleur, Bonnie J.;Nikolich, Janko Ž.;Sprissler, Ryan;Worobey, Michael;Bhattacharya, Deepta; Published Date : June 2025 Pages in Document : 829-836 (26 pdf pages) Source : Nature Immunology, 2025, v. 26, no. 6 DOI : https://doi.org/10.1038/s41590-025-02162-2 Journal Title : Nature Immunology
Quirk, G. E., Schoenle, M. V., Peyton, K. L., Uhrlaub, J. L., Lau, B., Liang, C. Y., Burgess, J. L., Ellingson, K., Beitel, S., Romine, J., Lutrick, K., Fowlkes, A., Britton, A., Tyner, H. L., Caban-Martinez, A. J., Naleway, A., Gaglani, M., Yoon, S., Edwards, L. J., ... Bhattacharya, D. (2025). Intrinsic Immunogenicity is a Major Determinant of Type-specific Responses in SARS-CoV-2 Infections. Nature Immunology, 26(6). https://doi.org/10.1038/s41590-025-02162-2

Quirk, Grace E., Marta V. Schoenle, Kameron L. Peyton, Jennifer L. Uhrlaub, Branden Lau, Chieh-Yu Liang, and Jefferey L. Burgess, et al.. "Intrinsic Immunogenicity is a Major Determinant of Type-specific Responses in SARS-CoV-2 Infections." Nature Immunology 26, no. 6 (2025). https://doi.org/10.1038/s41590-025-02162-2.

Quirk, Grace E., et al. "Intrinsic Immunogenicity is a Major Determinant of Type-specific Responses in SARS-CoV-2 Infections." Nature Immunology, vol. 26, no. 6, 2025. Stacks. https://doi.org/10.1038/s41590-025-02162-2.
Export RIS Citation Information. TY - Journal Article AU - Quirk, Grace E. AU - Schoenle, Marta V. AU - Peyton, Kameron L. AU - Uhrlaub, Jennifer L. AU - Lau, Branden AU - Liang, Chieh-Yu AU - Burgess, Jefferey L. AU - Ellingson, Katherine AU - Beitel, Shawn AU - Romine, James AU - Lutrick, Karen AU - Fowlkes, Ashley AU - Britton, Amadea AU - Tyner, Harmony L. AU - Caban-Martinez, Alberto J. AU - Naleway, Allison AU - Gaglani, Manjusha AU - Yoon, Sarang AU - Edwards, Laura J. AU - Olsho, Lauren AU - Dake, Michael AU - Valdez, Riccardo AU - Gordon, Aubree AU - Diamond, Michael S. AU - LaFleur, Bonnie J. AU - Nikolich, Janko Ž. AU - Sprissler, Ryan AU - Worobey, Michael AU - Bhattacharya, Deepta AB - Few type-specific antibodies that recognize drifted epitopes are made during post-vaccination exposures to SARS-CoV-2 variants AB - , perhaps due to suppression by previous immunity. We compared type-specific B cell responses in unvaccinated and vaccinated individuals with Delta and Omicron BA.1 SARS-CoV-2 variant infections. For both Delta, which is antigenically similar to the vaccine strain, and the more distant BA.1 variant, neutralizing antibodies were greater in post-vaccination variant infections than in primary variant infections. Delta type-specific memory B cells were reduced in post-vaccination Delta infections relative to primary variant infections. Yet some drifted epitopes in the Delta variant elicited minimal responses even in primary infections. For BA.1 infections, type-specific antibodies and memory B cells were mostly undetectable, irrespective of previous immunity. Thus, poor intrinsic antigenicity of drifted epitopes in Delta and BA.1 infections superseded the impact of previous immunity. Enhancing the immunogenicity of vaccine antigens may promote type-specific responses. AB - Author manuscript AN - cdc:261381 C4 - PMC12198969 DO - https://doi.org/10.1038/s41590-025-02162-2 IS - 6 J2 - Nature Immunology KW - Memory B Cells KW - B-Lymphocytes KW - Antibodies, Neutralizing KW - Female KW - Vaccination KW - SARS-CoV-2 KW - Immunologic Memory KW - COVID-19 KW - Epitopes, B-Lymphocyte KW - Immunogenicity, Vaccine KW - COVID-19 Vaccines KW - Antibodies, Viral KW - Male KW - Spike Glycoprotein, Coronavirus KW - Humans KW - Middle Aged KW - Adult KW - Humans KW - SARS-CoV-2 KW - COVID-19 KW - Antibodies, Viral KW - Antibodies, Neutralizing KW - COVID-19 Vaccines KW - Memory B Cells KW - Spike Glycoprotein, Coronavirus KW - Female KW - Middle Aged KW - Male KW - Epitopes, B-Lymphocyte KW - Immunologic Memory KW - Adult KW - Vaccination KW - Immunogenicity, Vaccine KW - B-Lymphocytes LA - eng PY - 2025 T2 - Nature Immunology T2 - Nature Immunology, 2025, v. 26, no. 6 TI - Intrinsic Immunogenicity is a Major Determinant of Type-specific Responses in SARS-CoV-2 Infections. VL - 26 UR - https://stacks.cdc.gov/view/cdc/261381 ER -
Advancing Methods For Program Evaluation in Substance Use by Strengthening the Application of Epidemiology, Economic Evaluation, and Implementation Science: Reflections on the Opportunities For Synergy.

Blackburn, Natalie A. ;

Philbrick, Sarah

August 2025 | Evaluation and Program Planning, 2025, v. 111

Program evaluation is necessary to assess the success of evidence-based programs in real-world, non-trial settings. In its most basic form, it involves understanding processes that impact the health and well-being of individuals and communities. Increasingly, robust program evaluations are integrating approaches from implementation science and econ ...

10/09/2026

Supporting Files

Title : Advancing Methods For Program Evaluation in Substance Use by Strengthening the Application of Epidemiology, Economic Evaluation, and Implementation Science: Reflections on the Opportunities For Synergy. Personal Author(s) : Blackburn, Natalie A.;Philbrick, Sarah;Patel, Sheila V.;Cance, Jessica D.;Elek, Elvira;Gibbons, Brent;Khan, Sazid;Lambdin, Barrot H.;Graham, Phillip W.; Published Date : August 2025 Pages in Document : 102610 (22 pdf pages) Source : Evaluation and Program Planning, 2025, v. 111 DOI : https://doi.org/10.1016/j.evalprogplan.2025.102610 Journal Title : Evaluation and Program Planning
Blackburn, N. A., Philbrick, S., Patel, S. V., Cance, J. D., Elek, E., Gibbons, B., Khan, S., Lambdin, B. H., & Graham, P. W. (2025). Advancing Methods For Program Evaluation in Substance Use by Strengthening the Application of Epidemiology, Economic Evaluation, and Implementation Science: Reflections on the Opportunities For Synergy. Evaluation and Program Planning, 111. https://doi.org/10.1016/j.evalprogplan.2025.102610

Blackburn, Natalie A., Sarah Philbrick, Sheila V. Patel, Jessica D. Cance, Elvira Elek, Brent Gibbons, Sazid Khan, Barrot H. Lambdin, and Phillip W. Graham. "Advancing Methods For Program Evaluation in Substance Use by Strengthening the Application of Epidemiology, Economic Evaluation, and Implementation Science: Reflections on the Opportunities For Synergy." Evaluation and Program Planning 111 (2025). https://doi.org/10.1016/j.evalprogplan.2025.102610.

Blackburn, Natalie A., et al. "Advancing Methods For Program Evaluation in Substance Use by Strengthening the Application of Epidemiology, Economic Evaluation, and Implementation Science: Reflections on the Opportunities For Synergy." Evaluation and Program Planning, vol. 111, 2025. Stacks. https://doi.org/10.1016/j.evalprogplan.2025.102610.
Export RIS Citation Information. TY - Journal Article AU - Blackburn, Natalie A. AU - Philbrick, Sarah AU - Patel, Sheila V. AU - Cance, Jessica D. AU - Elek, Elvira AU - Gibbons, Brent AU - Khan, Sazid AU - Lambdin, Barrot H. AU - Graham, Phillip W. AB - Program evaluation is necessary to assess the success of evidence-based programs in real-world, non-trial settings. In its most basic form, it involves understanding processes that impact the health and well-being of individuals and communities. Increasingly, robust program evaluations are integrating approaches from implementation science and economic evaluation to strengthen assessment, achievement, and sustainment of the intended impacts of evidence-based programs, while traditionally employing epidemiological methods to assess outcomes. Epidemiology, economic evaluation, and implementation science operate in overlapping yet siloed arenas, which can make it challenging for program evaluators to effectively engage all three disciplines. Furthermore, given their overlap, practitioners in these disciplines must understand differences in their purpose and lexicon to foster synergies. We use the Centers for Disease Control and Prevention Evaluation Framework and an example from substance use prevention to reflect on specific concepts and terminology within each of these disciplines and how distinctions impact the ability of multidisciplinary teams to collaborate on evaluations. The implications apply to those designing, testing, implementing, and evaluating evidence-based programs-all of whom have the opportunity to consider and strengthen these elements when developing processes and measuring impact. The substance use prevention field needs to better understand how these disciplines can complement one another to enrich process, outcome, and impact evaluations, given the complexities of substance use behaviors and evidence-based programs to address them. With this synergy, clearer communication of findings from the different components can be achieved. AB - Author manuscript AN - cdc:261380 C4 - PMC12439252 DO - https://doi.org/10.1016/j.evalprogplan.2025.102610 J2 - Evaluation and Program Planning KW - Implementation Science KW - Program Evaluation KW - Humans KW - Cost-Benefit Analysis KW - Substance-Related Disorders KW - Evidence-Based Practice KW - Centers for Disease Control and Prevention, U.S. KW - economic evaluation KW - epidemiology KW - implementation science KW - program evaluation KW - substance use prevention KW - Humans KW - Substance-Related Disorders KW - Implementation Science KW - Program Evaluation KW - Centers for Disease Control and Prevention, U.S. KW - Evidence-Based Practice KW - Cost-Benefit Analysis LA - eng PY - 2025 T2 - Evaluation and Program Planning T2 - Evaluation and Program Planning, 2025, v. 111 TI - Advancing Methods For Program Evaluation in Substance Use by Strengthening the Application of Epidemiology, Economic Evaluation, and Implementation Science: Reflections on the Opportunities For Synergy. VL - 111 UR - https://stacks.cdc.gov/view/cdc/261380 ER -
Swine Production Intensity and Swine-specific Fecal Contamination of Household Surfaces at Residences of Industrial Livestock Operation Workers and Community Residents, North Carolina, USA.

Kurowski, Kathleen M ;

Pisanic, Nora

July 2025 | The Science of the Total Environment, 2025, v. 985

In North Carolina (NC), industrial livestock operations (ILOs) that produce swine concentrate fecal waste in lagoons and sprayfields, which are disproportionately located in low-income communities of color. Although swine-specific fecal contamination of surface waters proximal to swine ILOs has been documented, less is known about contamination of ...

10/09/2026

Supporting Files

Title : Swine Production Intensity and Swine-specific Fecal Contamination of Household Surfaces at Residences of Industrial Livestock Operation Workers and Community Residents, North Carolina, USA. Personal Author(s) : Kurowski, Kathleen M;Pisanic, Nora;Spicer, Kristoffer;Kruczynski, Kate;Gigot, Carolyn;Hall, Devon J.;Aune, Kyle T.;Salmerón, Bonita;Rule, Ana M.;Heaney, Christopher D.; Published Date : July 2025 Pages in Document : 179591 (28 pdf pages) Source : The Science of the Total Environment, 2025, v. 985 DOI : https://doi.org/10.1016/j.scitotenv.2025.179591 Journal Title : The Science of the Total Environment
Kurowski, K. M., Pisanic, N., Spicer, K., Kruczynski, K., Gigot, C., Hall, D. J., Aune, K. T., Salmerón, B., Rule, A. M., & Heaney, C. D. (2025). Swine Production Intensity and Swine-specific Fecal Contamination of Household Surfaces at Residences of Industrial Livestock Operation Workers and Community Residents, North Carolina, USA. The Science of the Total Environment, 985. https://doi.org/10.1016/j.scitotenv.2025.179591

Kurowski, Kathleen M, Nora Pisanic, Kristoffer Spicer, Kate Kruczynski, Carolyn Gigot, Devon J. Hall, Kyle T. Aune, Bonita Salmerón, Ana M. Rule, and Christopher D. Heaney. "Swine Production Intensity and Swine-specific Fecal Contamination of Household Surfaces at Residences of Industrial Livestock Operation Workers and Community Residents, North Carolina, USA." The Science of the Total Environment 985 (2025). https://doi.org/10.1016/j.scitotenv.2025.179591.

Kurowski, Kathleen M, et al. "Swine Production Intensity and Swine-specific Fecal Contamination of Household Surfaces at Residences of Industrial Livestock Operation Workers and Community Residents, North Carolina, USA." The Science of the Total Environment, vol. 985, 2025. Stacks. https://doi.org/10.1016/j.scitotenv.2025.179591.
Export RIS Citation Information. TY - Journal Article AU - Kurowski, Kathleen M AU - Pisanic, Nora AU - Spicer, Kristoffer AU - Kruczynski, Kate AU - Gigot, Carolyn AU - Hall, Devon J. AU - Aune, Kyle T. AU - Salmerón, Bonita AU - Rule, Ana M. AU - Heaney, Christopher D. AB - In North Carolina (NC), industrial livestock operations (ILOs) that produce swine concentrate fecal waste in lagoons and sprayfields, which are disproportionately located in low-income communities of color. Although swine-specific fecal contamination of surface waters proximal to swine ILOs has been documented, less is known about contamination of homes proximal to swine ILOs. Up to 6 outdoor and 6 indoor surface settled dust samples were collected from households: 1) with >= 1 ILO worker (ILO-W); 2) neighboring ILOs without occupational exposure to livestock (ILO-N); and 3) in metropolitan areas of NC (Metro). Using quantitative real-time PCR, the DNA copy number of Pig-2-Bac, a swine-specific fecal microbial source tracking (MST) marker, per square inch of household surfaces sampled was measured. We used permits of swine ILOs and steady state live weight to assign swine production intensity (SPI) exposure values to each household. We estimated associations between household group (Metro as reference), outdoor versus indoor household surface, and log AB - SPI with Pig-2-Bac DNA detection frequency (logistic) and quantity (linear) via regression modeling. Prevalence of household Pig-2-Bac positivity was 38 % (40/105) at ILO-W (159/536 swabs; 30 %); 44 % (47/107) at ILO-N (142/557 swabs; 25 %), and 1 % (1/81) at Metro (1/321 swabs; 1 %) households. Pig-2-Bac DNA was detected more often (odds ratio [OR] = 2.2; 95 % confidence interval [CI] = 1.6, 3.0) and in higher quantity (β = 0.30; 95 % CI = 0.19, 0.41) on outdoor compared to indoor surfaces. For every log AB - unit increase in SPI, the Pig-2-Bac DNA detection frequency (OR = 5.4; 95 % CI = 2.8, 10.4) and quantity (β = 0.21; 95 % CI = 0.13, 0.29) increased. Results demonstrate the utility of Pig-2-Bac DNA measurement in household surface dust and suggest that swine ILOs contribute to the contamination of NC community residents' households with swine fecal material. AB - Author manuscript AN - cdc:261379 C4 - PMC13140102 DO - https://doi.org/10.1016/j.scitotenv.2025.179591 J2 - The Science of the Total Environment KW - Occupational Exposure KW - Swine KW - Dust KW - Animals KW - Feces KW - Humans KW - Environmental Monitoring KW - Environmental Exposure KW - Animal Husbandry KW - Livestock KW - Concentrated animal feeding operations (CAFOs) KW - Hog production KW - Swine KW - Pig-2-Bac KW - Environmental justice KW - fecal contamination KW - Microbial source tracking KW - Animals KW - Swine KW - Feces KW - Environmental Monitoring KW - Animal Husbandry KW - Humans KW - Dust KW - Livestock KW - Occupational Exposure KW - Environmental Exposure LA - eng PY - 2025 T2 - The Science of the Total Environment T2 - The Science of the Total Environment, 2025, v. 985 TI - Swine Production Intensity and Swine-specific Fecal Contamination of Household Surfaces at Residences of Industrial Livestock Operation Workers and Community Residents, North Carolina, USA. VL - 985 UR - https://stacks.cdc.gov/view/cdc/261379 ER -
Maternal Area of Residence and Outcomes For Mother-Infant Dyads With Perinatal Opioid Exposure.

Pahl, Adrienne ;

Hu, Zhuopei

February 2026 | American Journal of Perinatology, 2026, v. 43, no. 3

Determine the relationship between maternal Social Deprivation Index (SDI), a composite measure of area-level deprivation, and maternal characteristics and infant outcomes for mother-infant dyads with perinatal opioid exposure.Post hoc secondary analysis of 1,298 mother-infant dyads in the ESC-NOW study, a multicenter, stepped-wedge cluster-randomi ...

10/09/2026

Supporting Files

Title : Maternal Area of Residence and Outcomes For Mother-Infant Dyads With Perinatal Opioid Exposure. Personal Author(s) : Pahl, Adrienne;Hu, Zhuopei;Young, Leslie W.;Ramsey, Kara Wong;Whalen, Bonny L.;Akshatha, Akshatha;Benninger, Kristen L.;Fung, Camille M.;Howell, Meghan P.;Markee, Sofia;Das, Abhik;Crawford, Margaret M.;Trochinski, Lillian;Greenberg, Rachel G.;Smith, Brian;Ounpraseuth, Songthip T.;Merhar, Stephanie L.;Devlin, Lori A.;MacMillan, Kathryn Dee L.; Published Date : February 2026 Pages in Document : 383-395 (22 pdf pages) Source : American Journal of Perinatology, 2026, v. 43, no. 3 DOI : https://doi.org/10.1055/a-2622-3839 Journal Title : American Journal of Perinatology
Pahl, A., Hu, Z., Young, L. W., Ramsey, K. W., Whalen, B. L., Akshatha, A., Benninger, K. L., Fung, C. M., Howell, M. P., Markee, S., Das, A., Crawford, M. M., Trochinski, L., Greenberg, R. G., Smith, B., Ounpraseuth, S. T., Merhar, S. L., Devlin, L. A., & MacMillan, K. D. L. (2026). Maternal Area of Residence and Outcomes For Mother-Infant Dyads With Perinatal Opioid Exposure. American Journal of Perinatology, 43(3). https://doi.org/10.1055/a-2622-3839

Pahl, Adrienne, Zhuopei Hu, Leslie W. Young, Kara Wong Ramsey, Bonny L. Whalen, Akshatha Akshatha, and Kristen L. Benninger, et al.. "Maternal Area of Residence and Outcomes For Mother-Infant Dyads With Perinatal Opioid Exposure." American Journal of Perinatology 43, no. 3 (2026). https://doi.org/10.1055/a-2622-3839.

Pahl, Adrienne, et al. "Maternal Area of Residence and Outcomes For Mother-Infant Dyads With Perinatal Opioid Exposure." American Journal of Perinatology, vol. 43, no. 3, 2026. Stacks. https://doi.org/10.1055/a-2622-3839.
Export RIS Citation Information. TY - Journal Article AU - Pahl, Adrienne AU - Hu, Zhuopei AU - Young, Leslie W. AU - Ramsey, Kara Wong AU - Whalen, Bonny L. AU - Akshatha, Akshatha AU - Benninger, Kristen L. AU - Fung, Camille M. AU - Howell, Meghan P. AU - Markee, Sofia AU - Das, Abhik AU - Crawford, Margaret M. AU - Trochinski, Lillian AU - Greenberg, Rachel G. AU - Smith, Brian AU - Ounpraseuth, Songthip T. AU - Merhar, Stephanie L. AU - Devlin, Lori A. AU - MacMillan, Kathryn Dee L. AB - Determine the relationship between maternal Social Deprivation Index (SDI), a composite measure of area-level deprivation, and maternal characteristics and infant outcomes for mother-infant dyads with perinatal opioid exposure.Post hoc secondary analysis of 1,298 mother-infant dyads in the ESC-NOW study, a multicenter, stepped-wedge cluster-randomized controlled trial (2020-2022) conducted at 26 U.S. study hospitals. The 2016 American Community Survey was used to develop SDI scores based on the maternal zip code of residence at the time of delivery. Outcomes evaluated included receipt of pharmacologic treatment for neonatal opioid withdrawal syndrome (PT), receipt of breastmilk during hospital stay, direct breastfeeding at discharge, discharge disposition, and length of stay for infants who received PT (length of hospital stay, LOS).The median SDI score was 62 on a scale of 100. The high SDI group, with a score above the SDI median and more social deprivation, was less likely to receive adequate prenatal care or medication for opioid use disorder and more likely to be Black and/or Hispanic. The mean proportion of infants in the high SDI group was 6.2% points (relative risk [RR]: 0.89; 95% confidence interval [CI]: 0.80, 0.98) less likely to receive breastmilk during the newborn hospitalization and 7.3% points (RR: 0.91; 95% CI: 0.87, 0.96) less likely to be discharged home with a biological parent. There was no difference between the high and low SDI groups in receipt of PT, direct breastfeeding at discharge, or LOS.Mothers from high SDI communities with opioid exposure during pregnancy were less likely to receive the established standard of care and more likely to be Black and/or Hispanic. Infants born to these mothers were less likely to receive breastmilk and/or to be discharged home with a biological parent. Targeting interventions to mitigate the impact of social deprivation in high SDI communities may improve outcomes for opioid-exposed infants and their mothers. · Living in an area with high social deprivation was associated with differences in health outcomes.. · Mothers were more likely to be Black and/or Hispanic.. · Mothers were less likely to receive the standard of care during pregnancy.. · Infants were less likely to receive breastmilk and/or be discharged home with a biological parent.. · Interventions designed to address community social deprivation may improve outcomes.. AB - Author manuscript AN - cdc:261378 C4 - PMC12246980 DO - https://doi.org/10.1055/a-2622-3839 IS - 3 J2 - American Journal of Perinatology KW - Pregnancy KW - Female KW - Neonatal Abstinence Syndrome KW - Residence Characteristics KW - Infant, Newborn KW - Opioid-Related Disorders KW - Breast Feeding KW - Socioeconomic Factors KW - Prenatal Care KW - Mothers KW - Analgesics, Opioid KW - Length of Stay KW - Male KW - Humans KW - Adult KW - Social Deprivation KW - Neonatal Abstinence Syndrome KW - Opioid KW - Perinatal Care KW - Neonatal Opioid Withdrawal Syndrome KW - Residence Characteristics KW - Sociodemographic Factors KW - Humans KW - Female KW - Pregnancy KW - Neonatal Abstinence Syndrome KW - Infant, Newborn KW - Adult KW - Opioid-Related Disorders KW - Breast Feeding KW - Length of Stay KW - Residence Characteristics KW - Analgesics, Opioid KW - Mothers KW - Socioeconomic Factors KW - Male KW - Prenatal Care LA - eng PY - 2026 T2 - American Journal of Perinatology T2 - American Journal of Perinatology, 2026, v. 43, no. 3 TI - Maternal Area of Residence and Outcomes For Mother-Infant Dyads With Perinatal Opioid Exposure. VL - 43 UR - https://stacks.cdc.gov/view/cdc/261378 ER -
Efficacy of Bismuth Subsalicylate on the Prevention of Travellers' Diarrhoea, 2018-2023.

Angelo, Kristina M. ;

Salah, Zainab

October 2025 | Journal of Travel Medicine, 2025, v. 32, no. 6

Travellers' diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for the treatment of TD. BSS is also used off-label for the prevention of TD, based on studies from the 1980s indicating TD protection; however, these studies have limitations. The objective of this study was to determine the efficacy of B ...

10/09/2026

Supporting Files

Title : Efficacy of Bismuth Subsalicylate on the Prevention of Travellers' Diarrhoea, 2018-2023. Personal Author(s) : Angelo, Kristina M.;Salah, Zainab;Rogova, Marina;Plumb, Ian D.;Walker, Allison T.;Prentice-Mott, Graeme;Waraich, Charandeep;Kim, Sunkyung;Ryan, Edward;LaRocque, Regina C.;Oliver, Elizabeth;Heitzinger, Kristen;Allison Perry-Dow, K.;Connor, Bradley A.; Published Date : October 2025 Pages in Document : taaf047(17 pdf pages) Source : Journal of Travel Medicine, 2025, v. 32, no. 6 DOI : https://doi.org/10.1093/jtm/taaf047 Journal Title : Journal of Travel Medicine
Angelo, K. M., Salah, Z., Rogova, M., Plumb, I. D., Walker, A. T., Prentice-Mott, G., Waraich, C., Kim, S., Ryan, E., LaRocque, R. C., Oliver, E., Heitzinger, K., Allison Perry-Dow, K., & Connor, B. A. (2025). Efficacy of Bismuth Subsalicylate on the Prevention of Travellers' Diarrhoea, 2018-2023. Journal of Travel Medicine, 32(6). https://doi.org/10.1093/jtm/taaf047

Angelo, Kristina M., Zainab Salah, Marina Rogova, Ian D. Plumb, Allison T. Walker, Graeme Prentice-Mott, and Charandeep Waraich, et al.. "Efficacy of Bismuth Subsalicylate on the Prevention of Travellers' Diarrhoea, 2018-2023." Journal of Travel Medicine 32, no. 6 (2025). https://doi.org/10.1093/jtm/taaf047.

Angelo, Kristina M., et al. "Efficacy of Bismuth Subsalicylate on the Prevention of Travellers' Diarrhoea, 2018-2023." Journal of Travel Medicine, vol. 32, no. 6, 2025. Stacks. https://doi.org/10.1093/jtm/taaf047.
Export RIS Citation Information. TY - Journal Article AU - Angelo, Kristina M. AU - Salah, Zainab AU - Rogova, Marina AU - Plumb, Ian D. AU - Walker, Allison T. AU - Prentice-Mott, Graeme AU - Waraich, Charandeep AU - Kim, Sunkyung AU - Ryan, Edward AU - LaRocque, Regina C. AU - Oliver, Elizabeth AU - Heitzinger, Kristen AU - Allison Perry-Dow, K. AU - Connor, Bradley A. AB - Travellers' diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for the treatment of TD. BSS is also used off-label for the prevention of TD, based on studies from the 1980s indicating TD protection; however, these studies have limitations. The objective of this study was to determine the efficacy of BSS in the prevention of TD. AB - This study was a prospective, double-blinded, placebo-controlled, randomized clinical trial (NCT03535272) with two arms: BSS 4 tablets twice daily (2.1 grams of BSS total) vs placebo. Travellers were included if they were ≥ 18 and < 70 years of age at the time of enrollment, were leaving for an international trip ≥7 days after their pretravel consultation, travelling in country for ≥7 days but ≤ 21 days, and travelling to either Southeast Asia, South Central Asia, North Africa, or Sub-Saharan Africa. Self-completed web-based questionnaires were administered before, during, and after travel. AB - 270 participants were included. The median age was 32 years (Interquartile range [IQR]: 27-44); 63% were female. Travellers were most frequently White (144; 61%) and non-Hispanic (239; 94%). The most frequent country of travel was Kenya (n = 87; 32%). The median total trip duration was 10 days ([IQR]: 8-13). The most frequent reason for travel was leisure/tourism (230, 85%). There was no significant difference among the groups for symptoms of loose stool and/or diarrhoea, although target sample size was not reached. AB - This study provides the first new data since the 1980s about the potential use of BSS in the prevention of TD. These data should not be viewed as evidence in isolation because of sample size constraints; further studies are needed to determine if there is a benefit in certain traveller groups or under certain circumstances. AB - Author manuscript AN - cdc:261377 C4 - PMC12439095 DO - https://doi.org/10.1093/jtm/taaf047 IS - 6 J2 - Journal of Travel Medicine KW - Double-Blind Method KW - Treatment Outcome KW - Female KW - Antidiarrheals KW - Prospective Studies KW - Young Adult KW - Organometallic Compounds KW - Salicylates KW - Diarrhea KW - Travel-Related Illness KW - Male KW - Middle Aged KW - Humans KW - Bismuth KW - Travel KW - Adult KW - Travellers' diarrhoea KW - travel KW - prevention KW - Humans KW - Diarrhea KW - Bismuth KW - Female KW - Salicylates KW - Male KW - Adult KW - Organometallic Compounds KW - Double-Blind Method KW - Prospective Studies KW - Travel KW - Middle Aged KW - Travel-Related Illness KW - Antidiarrheals KW - Treatment Outcome KW - Young Adult LA - eng PY - 2025 T2 - Journal of Travel Medicine T2 - Journal of Travel Medicine, 2025, v. 32, no. 6 TI - Efficacy of Bismuth Subsalicylate on the Prevention of Travellers' Diarrhoea, 2018-2023. VL - 32 UR - https://stacks.cdc.gov/view/cdc/261377 ER -
Estimating the Long-term Health Impact and Program Cost-effectiveness of Providing Direct Screening Services to Low-income, Medically Underserved Patients Through the Colorectal Cancer Control Program (CRCCP).

O'Leary, Meghan C. ;

Koutouan, Priscille R.

August 4, 2025 | Cancer Causes & Control: CCC, 2025, v. 36, no. 10

The Colorectal Cancer Control Program (CRCCP) aimed to increase colorectal cancer (CRC) screening among U.S. medically underserved populations through promotion and provision of CRC screening. We used simulation modeling to estimate the lifelong health impact and program cost-effectiveness of direct screening services, typically a single cycle of r ...

10/09/2026

Supporting Files

Title : Estimating the Long-term Health Impact and Program Cost-effectiveness of Providing Direct Screening Services to Low-income, Medically Underserved Patients Through the Colorectal Cancer Control Program (CRCCP). Personal Author(s) : O'Leary, Meghan C.;Koutouan, Priscille R.;Mayorga, Maria E.;Sharma, Krishna P.;DeGroff, Amy;Richardson, Lisa C.;Lich, Kristen Hassmiller; Published Date : August 4, 2025 Pages in Document : 1175-1195 (23 pdf pages) Source : Cancer Causes & Control: CCC, 2025, v. 36, no. 10 DOI : https://doi.org/10.1007/s10552-025-01994-5 Journal Title : Cancer Causes & Control: CCC
O'Leary, M. C., Koutouan, P. R., Mayorga, M. E., Sharma, K. P., DeGroff, A., Richardson, L. C., & Lich, K. H. (2025). Estimating the Long-term Health Impact and Program Cost-effectiveness of Providing Direct Screening Services to Low-income, Medically Underserved Patients Through the Colorectal Cancer Control Program (CRCCP). Cancer Causes & Control: CCC, 36(10). https://doi.org/10.1007/s10552-025-01994-5

O'Leary, Meghan C., Priscille R. Koutouan, Maria E. Mayorga, Krishna P. Sharma, Amy DeGroff, Lisa C. Richardson, and Kristen Hassmiller Lich. "Estimating the Long-term Health Impact and Program Cost-effectiveness of Providing Direct Screening Services to Low-income, Medically Underserved Patients Through the Colorectal Cancer Control Program (CRCCP)." Cancer Causes & Control: CCC 36, no. 10 (2025). https://doi.org/10.1007/s10552-025-01994-5.

O'Leary, Meghan C., et al. "Estimating the Long-term Health Impact and Program Cost-effectiveness of Providing Direct Screening Services to Low-income, Medically Underserved Patients Through the Colorectal Cancer Control Program (CRCCP)." Cancer Causes & Control: CCC, vol. 36, no. 10, 2025. Stacks. https://doi.org/10.1007/s10552-025-01994-5.
Export RIS Citation Information. TY - Journal Article AU - O'Leary, Meghan C. AU - Koutouan, Priscille R. AU - Mayorga, Maria E. AU - Sharma, Krishna P. AU - DeGroff, Amy AU - Richardson, Lisa C. AU - Lich, Kristen Hassmiller AB - The Colorectal Cancer Control Program (CRCCP) aimed to increase colorectal cancer (CRC) screening among U.S. medically underserved populations through promotion and provision of CRC screening. We used simulation modeling to estimate the lifelong health impact and program cost-effectiveness of direct screening services, typically a single cycle of routine screening/follow-up testing provided through the CRCCP ("intervention"). AB - Data for this study were from CDC's Colorectal Clinical Data Elements (CCDE), which captured screening and follow-up services received from CRCCP between 2009 and 2020. We used microsimulation to model the evolution of polyps and CRC for average-risk individuals in intervention and "counterfactual" (control) groups, under multiple scenarios. We calculated and compared lifetime CRC outcomes (cases, deaths, life-years) for individuals with and without the CRCCP intervention. Clinical and implementation costs incurred by the CRCCP were used to estimate programmatic/intervention costs. Results are reported overall and by initial screening modality received (colonoscopy or stool testing) and assumed lower vs. higher "background" (non-intervention) screening scenarios. AB - With conservative assumptions, our findings suggest that CRCCP-provided screening averted 806 CRC cases, avoided 392 CRC deaths, and added 5,368 life-years per 100,000 individuals vs. no intervention. Cost-effectiveness analysis revealed that the program's cost per life-year gained varied by screening modality and scenario assumptions-ranging from $25,740 to $27,583 for colonoscopy screening and $70,410 to $75,979 for stool testing. AB - CRCCP-provided screening/testing services were found to produce substantial potential health gains. Our analysis estimates the cost-effectiveness of providing one cycle of screening/testing to medically underserved individuals to inform programmatic decisions. AB - Author manuscript AN - cdc:261376 C4 - PMC12320612 DO - https://doi.org/10.1007/s10552-025-01994-5 IS - 10 J2 - Cancer Causes & Control: CCC KW - Female KW - Colonoscopy KW - Colorectal Neoplasms KW - Mass Screening KW - Medically Underserved Area KW - Male KW - Aged KW - Humans KW - Poverty KW - Cost-Benefit Analysis KW - Middle Aged KW - Early Detection of Cancer KW - Colorectal cancer screening KW - Simulation KW - Economic evaluation KW - Medically underserved populations KW - Humans KW - Colorectal Neoplasms KW - Cost-Benefit Analysis KW - Early Detection of Cancer KW - Female KW - Male KW - Middle Aged KW - Poverty KW - Aged KW - Medically Underserved Area KW - Mass Screening KW - Colonoscopy LA - eng PY - 2025 T2 - Cancer Causes & Control: CCC T2 - Cancer Causes & Control: CCC, 2025, v. 36, no. 10 TI - Estimating the Long-term Health Impact and Program Cost-effectiveness of Providing Direct Screening Services to Low-income, Medically Underserved Patients Through the Colorectal Cancer Control Program (CRCCP). VL - 36 UR - https://stacks.cdc.gov/view/cdc/261376 ER -
Acute Gastroenteritis Among Household Contacts of Children With Severe Norovirus Gastroenteritis, United States, 2011-2016.

Moran, Mary C. ;

Wikswo, Mary E.

June 2025 | Journal of the Pediatric Infectious Diseases Society, 2025, v. 14, no. 6

Norovirus-associated acute gastroenteritis (AGE) in children <11 years resulted in substantial AGE illness among household contacts (HHCs). Vomiting (≥5 episodes in 24 hours) was the greatest risk factor (aOR, 2.85, [95% CI, 1.91-4.26]) for AGE symptoms among HHCs of norovirus-positive index cases. HHCs age 0-4 years had the highest attack rates (22%).

10/09/2026

Supporting Files

Title : Acute Gastroenteritis Among Household Contacts of Children With Severe Norovirus Gastroenteritis, United States, 2011-2016. Personal Author(s) : Moran, Mary C.;Wikswo, Mary E.;Selvarangan, Rangaraj;Harrison, Christopher J.;Sahni, Leila C.;Boom, Julie A.;Halasa, Natasha;Stewart, Laura S.;Payne, Daniel C.;Staat, Mary Allen;Weinberg, Geoffrey A.;Szilagyi, Peter G.;Englund, Janet A.;Klein, Eileen J.;Vinjé, Jan;Parashar, Umesh D.;Tate, Jaqueline E.;Mirza, Sara A.; Published Date : June 2025 Pages in Document : piaf049(13 pdf pages) Source : Journal of the Pediatric Infectious Diseases Society, 2025, v. 14, no. 6 DOI : https://doi.org/10.1093/jpids/piaf049 Journal Title : Journal of the Pediatric Infectious Diseases Society
Moran, M. C., Wikswo, M. E., Selvarangan, R., Harrison, C. J., Sahni, L. C., Boom, J. A., Halasa, N., Stewart, L. S., Payne, D. C., Staat, M. A., Weinberg, G. A., Szilagyi, P. G., Englund, J. A., Klein, E. J., Vinjé, J., Parashar, U. D., Tate, J. E., & Mirza, S. A. (2025). Acute Gastroenteritis Among Household Contacts of Children With Severe Norovirus Gastroenteritis, United States, 2011-2016. Journal of the Pediatric Infectious Diseases Society, 14(6). https://doi.org/10.1093/jpids/piaf049

Moran, Mary C., Mary E. Wikswo, Rangaraj Selvarangan, Christopher J. Harrison, Leila C. Sahni, Julie A. Boom, and Natasha Halasa, et al.. "Acute Gastroenteritis Among Household Contacts of Children With Severe Norovirus Gastroenteritis, United States, 2011-2016." Journal of the Pediatric Infectious Diseases Society 14, no. 6 (2025). https://doi.org/10.1093/jpids/piaf049.

Moran, Mary C., et al. "Acute Gastroenteritis Among Household Contacts of Children With Severe Norovirus Gastroenteritis, United States, 2011-2016." Journal of the Pediatric Infectious Diseases Society, vol. 14, no. 6, 2025. Stacks. https://doi.org/10.1093/jpids/piaf049.
Export RIS Citation Information. TY - Journal Article AU - Moran, Mary C. AU - Wikswo, Mary E. AU - Selvarangan, Rangaraj AU - Harrison, Christopher J. AU - Sahni, Leila C. AU - Boom, Julie A. AU - Halasa, Natasha AU - Stewart, Laura S. AU - Payne, Daniel C. AU - Staat, Mary Allen AU - Weinberg, Geoffrey A. AU - Szilagyi, Peter G. AU - Englund, Janet A. AU - Klein, Eileen J. AU - Vinjé, Jan AU - Parashar, Umesh D. AU - Tate, Jaqueline E. AU - Mirza, Sara A. AB - Norovirus-associated acute gastroenteritis (AGE) in children <11 years resulted in substantial AGE illness among household contacts (HHCs). Vomiting (≥5 episodes in 24 hours) was the greatest risk factor (aOR, 2.85, [95% CI, 1.91-4.26]) for AGE symptoms among HHCs of norovirus-positive index cases. HHCs age 0-4 years had the highest attack rates (22%). AB - Author manuscript AN - cdc:261375 C4 - PMC12928128 DO - https://doi.org/10.1093/jpids/piaf049 IS - 6 J2 - Journal of the Pediatric Infectious Diseases Society KW - Adolescent KW - Female KW - Gastroenteritis KW - Family Characteristics KW - Infant, Newborn KW - Norovirus KW - Child KW - Risk Factors KW - Infant KW - Acute Disease KW - Vomiting KW - Male KW - Humans KW - Child, Preschool KW - Caliciviridae Infections KW - Adult KW - Norovirus KW - acute gastroenteritis KW - household transmission KW - Humans KW - Gastroenteritis KW - Caliciviridae Infections KW - Child, Preschool KW - Infant KW - Norovirus KW - Male KW - Female KW - Child KW - Acute Disease KW - Family Characteristics KW - Risk Factors KW - Infant, Newborn KW - Adolescent KW - Adult KW - Vomiting LA - eng PY - 2025 T2 - Journal of the Pediatric Infectious Diseases Society T2 - Journal of the Pediatric Infectious Diseases Society, 2025, v. 14, no. 6 TI - Acute Gastroenteritis Among Household Contacts of Children With Severe Norovirus Gastroenteritis, United States, 2011-2016. VL - 14 UR - https://stacks.cdc.gov/view/cdc/261375 ER -
Evaluation of 7 Urinary Metabolites of Polycyclic Aromatic Hydrocarbons During a Wildfire Response as Part of the Wildland Firefighter Exposure and Health Effects Study.

Mayer, Alexander C. ;

Fent, Kenneth W.

June 2025 | Annals of Work Exposures and Health, 2025, v. 69, no. 5

The occupation of firefighting, including wildland firefighting, has been classified as a known human carcinogen by the International Agency for Research on Cancer. Wildland firefighters (WFFs) can be exposed to polycyclic aromatic hydrocarbons (PAHs) present in wildfire smoke, some of which are known or probable carcinogens. Currently, there is no ...

10/09/2026

Supporting Files

Title : Evaluation of 7 Urinary Metabolites of Polycyclic Aromatic Hydrocarbons During a Wildfire Response as Part of the Wildland Firefighter Exposure and Health Effects Study. Personal Author(s) : Mayer, Alexander C.;Fent, Kenneth W.;Chen, I-Chen;DuBose, Kathleen Navarro;Butler, Corey R.;West, Molly;Calafat, Antonia M.;Botelho, Julianne Cook;Toennis, Christine;Meadows, Juliana;Sammons, Deborah; Published Date : June 2025 Pages in Document : 559-567 (11 pdf pages) Source : Annals of Work Exposures and Health, 2025, v. 69, no. 5 DOI : https://doi.org/10.1093/annweh/wxaf024 Journal Title : Annals of Work Exposures and Health
Mayer, A. C., Fent, K. W., Chen, I. C., DuBose, K. N., Butler, C. R., West, M., Calafat, A. M., Botelho, J. C., Toennis, C., Meadows, J., & Sammons, D. (2025). Evaluation of 7 Urinary Metabolites of Polycyclic Aromatic Hydrocarbons During a Wildfire Response as Part of the Wildland Firefighter Exposure and Health Effects Study. Annals of Work Exposures and Health, 69(5). https://doi.org/10.1093/annweh/wxaf024

Mayer, Alexander C., Kenneth W. Fent, I-Chen Chen, Kathleen Navarro DuBose, Corey R. Butler, Molly West, and Antonia M. Calafat, et al.. "Evaluation of 7 Urinary Metabolites of Polycyclic Aromatic Hydrocarbons During a Wildfire Response as Part of the Wildland Firefighter Exposure and Health Effects Study." Annals of Work Exposures and Health 69, no. 5 (2025). https://doi.org/10.1093/annweh/wxaf024.

Mayer, Alexander C., et al. "Evaluation of 7 Urinary Metabolites of Polycyclic Aromatic Hydrocarbons During a Wildfire Response as Part of the Wildland Firefighter Exposure and Health Effects Study." Annals of Work Exposures and Health, vol. 69, no. 5, 2025. Stacks. https://doi.org/10.1093/annweh/wxaf024.
Export RIS Citation Information. TY - Journal Article AU - Mayer, Alexander C. AU - Fent, Kenneth W. AU - Chen, I-Chen AU - DuBose, Kathleen Navarro AU - Butler, Corey R. AU - West, Molly AU - Calafat, Antonia M. AU - Botelho, Julianne Cook AU - Toennis, Christine AU - Meadows, Juliana AU - Sammons, Deborah AB - The occupation of firefighting, including wildland firefighting, has been classified as a known human carcinogen by the International Agency for Research on Cancer. Wildland firefighters (WFFs) can be exposed to polycyclic aromatic hydrocarbons (PAHs) present in wildfire smoke, some of which are known or probable carcinogens. Currently, there is no approved respiratory protection for WFFs against wildfire smoke, making inhalation exposure to PAHs a health concern. Recent studies have also highlighted the risk of dermal exposure to PAHs for WFFs due to factors like elevated skin temperature, sweat, and the inability to shower or routinely conduct good skin hygiene practices during wildfire incidents. This pilot study aimed to assess PAH exposure among 19 WFFs in different job positions during a wildfire incident by determining urine concentrations of 7 PAH metabolites in samples collected before and after shifts across 3 days. Overall, we observed increases from pre- to post-shift for all 7 PAH metabolites when we combined all WFF samples across the 3 days. When we stratified by job position and by day, concentrations of the PAH metabolites significantly increased from pre- to post-shift for 88% (37/42) of the comparisons (P-values <0.05). Additionally, median post-shift creatinine-corrected concentrations of 2-hydroxynaphthalene exceeded the 95th percentile of the nonsmoking US general population in 67% (4/6) of comparisons. Post-shift concentrations of hydroxynaphthalenes also exceeded concentrations measured in structural firefighters responding to training fires. Overall, 2-hydroxynaphthalene was highest on Day 2 (median creatinine-corrected concentrations of 2-hydroxynaphthalene from pre- to post-shift increased 425% for crew member/overhead; 146% for saw team). Despite this finding, we did not observe significant differences by job position. However, future studies could evaluate how job position affects WFF exposures while also exploring how dermal and inhalation contribute to WFFs' PAH exposure burden. AB - Author manuscript AN - cdc:261374 C4 - PMC12230813 DO - https://doi.org/10.1093/annweh/wxaf024 IS - 5 J2 - Annals of Work Exposures and Health KW - Occupational Exposure KW - Adolescent KW - Smoke KW - Prospective Studies KW - Inhalation Exposure KW - Young Adult KW - Skin Absorption KW - Polycyclic Aromatic Hydrocarbons KW - Wildfires KW - Air Pollutants, Occupational KW - Firefighters KW - Carcinogens, Environmental KW - Male KW - Pilot Projects KW - Humans KW - Middle Aged KW - Adult KW - Wildfires KW - Firefighters KW - Occupational Exposure KW - Polycyclic Aromatic Hydrocarbons KW - Carcinogens, Environmental KW - Smoke KW - Air Pollutants, Occupational KW - Inhalation Exposure KW - Skin Absorption KW - Prospective Studies KW - Pilot Projects KW - Humans KW - Male KW - Adolescent KW - Young Adult KW - Adult KW - Middle Aged LA - eng PY - 2025 T2 - Annals of Work Exposures and Health T2 - Annals of Work Exposures and Health, 2025, v. 69, no. 5 TI - Evaluation of 7 Urinary Metabolites of Polycyclic Aromatic Hydrocarbons During a Wildfire Response as Part of the Wildland Firefighter Exposure and Health Effects Study. VL - 69 UR - https://stacks.cdc.gov/view/cdc/261374 ER -
Prioritizing Interventions to Address Healthcare Worker Barriers to Reporting Adverse Events Following Immunization in Ghana.

Laryea, Sharon ;

Blau, Erin

July 2025 | Vaccine, 2025, v. 60

Despite increasing global efforts to enhance vaccine safety, there are still major gaps in the African subregion's capacity to adequately monitor and respond to vaccine concerns. In 2017 and 2019, two assessments were conducted in Ghana to identify barriers to adverse events following immunization (AEFI) reporting among healthcare workers (HCWs), w ...

10/09/2026

Supporting Files

Title : Prioritizing Interventions to Address Healthcare Worker Barriers to Reporting Adverse Events Following Immunization in Ghana. Personal Author(s) : Laryea, Sharon;Blau, Erin;Dodoo, Alexander;Addo, Evelyn;Owusu-Boakye, Bernice;Amponsa-Achiano, Kwame;Mohammed, Naziru Tanko;Asamoa-Amoakohene, Abena;Gidudu, Jane; Published Date : July 2025 Pages in Document : 127324 (11 pdf pages) Source : Vaccine, 2025, v. 60 DOI : https://doi.org/10.1016/j.vaccine.2025.127324 Journal Title : Vaccine
Laryea, S., Blau, E., Dodoo, A., Addo, E., Owusu-Boakye, B., Amponsa-Achiano, K., Mohammed, N. T., Asamoa-Amoakohene, A., & Gidudu, J. (2025). Prioritizing Interventions to Address Healthcare Worker Barriers to Reporting Adverse Events Following Immunization in Ghana. Vaccine, 60. https://doi.org/10.1016/j.vaccine.2025.127324

Laryea, Sharon, Erin Blau, Alexander Dodoo, Evelyn Addo, Bernice Owusu-Boakye, Kwame Amponsa-Achiano, Naziru Tanko Mohammed, Abena Asamoa-Amoakohene, and Jane Gidudu. "Prioritizing Interventions to Address Healthcare Worker Barriers to Reporting Adverse Events Following Immunization in Ghana." Vaccine 60 (2025). https://doi.org/10.1016/j.vaccine.2025.127324.

Laryea, Sharon, et al. "Prioritizing Interventions to Address Healthcare Worker Barriers to Reporting Adverse Events Following Immunization in Ghana." Vaccine, vol. 60, 2025. Stacks. https://doi.org/10.1016/j.vaccine.2025.127324.
Export RIS Citation Information. TY - Journal Article AU - Laryea, Sharon AU - Blau, Erin AU - Dodoo, Alexander AU - Addo, Evelyn AU - Owusu-Boakye, Bernice AU - Amponsa-Achiano, Kwame AU - Mohammed, Naziru Tanko AU - Asamoa-Amoakohene, Abena AU - Gidudu, Jane AB - Despite increasing global efforts to enhance vaccine safety, there are still major gaps in the African subregion's capacity to adequately monitor and respond to vaccine concerns. In 2017 and 2019, two assessments were conducted in Ghana to identify barriers to adverse events following immunization (AEFI) reporting among healthcare workers (HCWs), which revealed multiple barriers and significant gaps in the reporting process, underscoring the need to evaluate approaches to enhance training and support for frontline HCWs. Building upon these assessment findings, in 2021 key immunization safety stakeholders in Ghana met to address the persistent barriers hindering effective reporting practices. Using a feasibility-impact matrix and other qualitative factors, structured discussions allowed stakeholders to identify four innovative strategies to improve AEFI reporting: AEFI reporting toolkit and job aid, HCW protection policy, and new hire training package. Design and implementation of these interventions will allow Ghana to address ongoing barriers to AEFI reporting. AB - Author manuscript AN - cdc:261373 C4 - PMC12230940 DO - https://doi.org/10.1016/j.vaccine.2025.127324 J2 - Vaccine KW - Adverse Drug Reaction Reporting Systems KW - Immunization KW - Vaccines KW - Vaccination KW - Humans KW - Health Personnel KW - Reporting barriers KW - Adverse events following immunization KW - Frontline immunization healthcare workers KW - Humans KW - Health Personnel KW - Adverse Drug Reaction Reporting Systems KW - Immunization KW - Vaccines KW - Vaccination LA - eng PY - 2025 T2 - Vaccine T2 - Vaccine, 2025, v. 60 TI - Prioritizing Interventions to Address Healthcare Worker Barriers to Reporting Adverse Events Following Immunization in Ghana. VL - 60 UR - https://stacks.cdc.gov/view/cdc/261373 ER -
Review of Cannabis-Related Programmatic Activities For Drug-Free Communities (DFC) Support Program Coalitions.

Mallory, Vanessa ;

Guarnizo, Julie

October 2025 | Journal of Community Health, 2025, v. 50, no. 5

Legalization by states of medical and non-medical cannabis use is increasing the accessibility of cannabis to Americans. While cannabis use remains illegal for youth, enhanced effective approaches preventing youth's cannabis use are important. The Drug-Free Communities (DFC) Support Program is administered by the White House Office of National Drug ...

10/09/2026

Supporting Files

Title : Review of Cannabis-Related Programmatic Activities For Drug-Free Communities (DFC) Support Program Coalitions. Personal Author(s) : Mallory, Vanessa;Guarnizo, Julie;Holland, Kristin;Fogarty, Hannah;Voetsch, Karen;Roehler, Douglas; Published Date : October 2025 Pages in Document : 965-974 (16 pdf pages) Source : Journal of Community Health, 2025, v. 50, no. 5 DOI : https://doi.org/10.1007/s10900-025-01477-3 Journal Title : Journal of Community Health
Mallory, V., Guarnizo, J., Holland, K., Fogarty, H., Voetsch, K., & Roehler, D. (2025). Review of Cannabis-Related Programmatic Activities For Drug-Free Communities (DFC) Support Program Coalitions. Journal of Community Health, 50(5). https://doi.org/10.1007/s10900-025-01477-3

Mallory, Vanessa, Julie Guarnizo, Kristin Holland, Hannah Fogarty, Karen Voetsch, and Douglas Roehler. "Review of Cannabis-Related Programmatic Activities For Drug-Free Communities (DFC) Support Program Coalitions." Journal of Community Health 50, no. 5 (2025). https://doi.org/10.1007/s10900-025-01477-3.

Mallory, Vanessa, et al. "Review of Cannabis-Related Programmatic Activities For Drug-Free Communities (DFC) Support Program Coalitions." Journal of Community Health, vol. 50, no. 5, 2025. Stacks. https://doi.org/10.1007/s10900-025-01477-3.
Export RIS Citation Information. TY - Journal Article AU - Mallory, Vanessa AU - Guarnizo, Julie AU - Holland, Kristin AU - Fogarty, Hannah AU - Voetsch, Karen AU - Roehler, Douglas AB - Legalization by states of medical and non-medical cannabis use is increasing the accessibility of cannabis to Americans. While cannabis use remains illegal for youth, enhanced effective approaches preventing youth's cannabis use are important. The Drug-Free Communities (DFC) Support Program is administered by the White House Office of National Drug Control Policy and represents the nation's leading effort to mobilize communities to prevent and reduce youth substance use. Coalitions use the Seven Strategies for Community Change to ensure the creation of comprehensive action plans and a community-wide approach for preventing youth substance use. This study's objective is to review the cannabis programmatic activities implemented by DFC coalitions, identify common themes, and assess whether activities align with the Seven Strategies for Community Change. Review of biannual progress report (PR) data collected from August 2020 to February 2021 was conducted to determine common themes, strengths, and areas of improvement among cannabis programmatic activities. Of the 727 funded coalitions, 73% (n = 532) identified cannabis as a substance they focused their activities on in their PR submissions, and 488 unique cannabis programmatic activities were reviewed. Cannabis programmatic activities were assigned to one of six common themes: 1) dissemination (n = 167), 2) training and education (n = 147), 3) community partnerships (n = 99), 4) policy and enforcement (n = 51), 5) miscellaneous (n = 15), and 6) communities of focus (n = 9). Findings could inform local organizations about common types of youth cannabis-related prevention activities implemented at the community-level. The least commonly reported strategies, such as communities of focus, may highlight opportunities for expanded prevention efforts for coalitions. AB - Author manuscript AN - cdc:261372 C4 - PMC13478901 DO - https://doi.org/10.1007/s10900-025-01477-3 IS - 5 J2 - Journal of Community Health KW - Cannabis KW - Adolescent KW - Marijuana Use KW - Drug and Narcotic Control KW - Humans KW - Substance-Related Disorders KW - United States KW - Cannabis Use KW - Youth Substance Use KW - Community Coalitions KW - Substance Use Prevention KW - Adolescent KW - Humans KW - Cannabis KW - United States KW - Marijuana Use KW - Drug and Narcotic Control KW - Substance-Related Disorders LA - eng PY - 2025 T2 - Journal of Community Health T2 - Journal of Community Health, 2025, v. 50, no. 5 TI - Review of Cannabis-Related Programmatic Activities For Drug-Free Communities (DFC) Support Program Coalitions. VL - 50 UR - https://stacks.cdc.gov/view/cdc/261372 ER -

Previous Page Previous

1141 - 1160 / 2104

Next Page Next

Found an issue?

Send us an email at: publishinghd@cdc.gov